<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Glutaryl-CoA Dehydrogenase Deficiency - Disorder Mechanisms</title>
    <style>
        :root {
            --primary: #0f766e;
            --primary-light: #14b8a6;
            --primary-dark: #0d5c56;
            --secondary: #6366f1;
            --bg: #f0fdfa;
            --card-bg: #ffffff;
            --text: #134e4a;
            --text-muted: #5f7a78;
            --border: #ccfbf1;
            --accent-orange: #f59e0b;
            --accent-rose: #f43f5e;
            --accent-violet: #8b5cf6;
            --accent-sky: #0ea5e9;
            --banner-bg: #fef3c7;
            --banner-border: #f59e0b;
            --banner-text: #92400e;
        }

        * { box-sizing: border-box; margin: 0; padding: 0; }

        body {
            font-family: 'Segoe UI', system-ui, -apple-system, sans-serif;
            background: var(--bg);
            color: var(--text);
            line-height: 1.7;
        }

        .notice-banner {
            background: var(--banner-bg);
            color: var(--banner-text);
            border-bottom: 1px solid var(--banner-border);
            padding: 12px 16px;
            text-align: center;
            font-size: 0.95rem;
            cursor: pointer;
        }

        .container {
            max-width: 1100px;
            margin: 0 auto;
            padding: 24px;
        }

        /* Header */
        .page-header {
            background: linear-gradient(135deg, var(--primary) 0%, var(--primary-dark) 100%);
            color: white;
            padding: 40px 32px;
            border-radius: 16px;
            margin-bottom: 24px;
            position: relative;
            overflow: hidden;
        }

        .page-header::before {
            content: '';
            position: absolute;
            top: -50%;
            right: -20%;
            width: 400px;
            height: 400px;
            background: rgba(255,255,255,0.05);
            border-radius: 50%;
        }

        .page-header h1 {
            font-size: 2.2rem;
            font-weight: 700;
            margin-bottom: 12px;
            position: relative;
        }

        .header-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 12px;
            align-items: center;
            position: relative;
        }

        .badge {
            display: inline-flex;
            align-items: center;
            padding: 6px 14px;
            border-radius: 20px;
            font-size: 0.85rem;
            font-weight: 500;
        }

        .badge-category {
            background: rgba(255,255,255,0.2);
            color: white;
        }

        .badge-mondo {
            background: var(--accent-sky);
            color: white;
        }

        .badge-mondo a {
            color: inherit;
            text-decoration: none;
        }

        .badge-mondo a:hover {
            text-decoration: underline;
        }

        /* Navigation */
        .breadcrumb {
            margin-bottom: 16px;
            font-size: 0.9rem;
        }

        .breadcrumb a {
            color: var(--primary);
            text-decoration: none;
        }

        .breadcrumb a:hover {
            text-decoration: underline;
        }

        .breadcrumb span {
            color: var(--text-muted);
        }

        /* Cards */
        .card {
            background: var(--card-bg);
            border-radius: 12px;
            border: 1px solid var(--border);
            padding: 24px;
            margin-bottom: 20px;
            box-shadow: 0 1px 3px rgba(0,0,0,0.04);
        }

        .card-header {
            display: flex;
            align-items: center;
            gap: 12px;
            margin-bottom: 16px;
            padding-bottom: 12px;
            border-bottom: 2px solid var(--border);
        }

        .card-icon {
            width: 36px;
            height: 36px;
            border-radius: 8px;
            display: flex;
            align-items: center;
            justify-content: center;
            font-size: 1.2rem;
        }

        .card-title {
            font-size: 1.1rem;
            font-weight: 600;
            color: var(--text);
        }

        .card-count {
            margin-left: auto;
            background: var(--bg);
            padding: 4px 12px;
            border-radius: 12px;
            font-size: 0.8rem;
            color: var(--text-muted);
        }

        /* Sections */
        .section-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(320px, 1fr));
            gap: 20px;
        }

        /* Tags */
        .tag-list {
            display: flex;
            flex-wrap: wrap;
            gap: 8px;
        }

        .tag {
            padding: 6px 12px;
            border-radius: 6px;
            font-size: 0.85rem;
            font-weight: 500;
        }

        .tag-cell {
            background: #fce7f3;
            color: #9d174d;
        }

        .tag-gene {
            background: #dbeafe;
            color: #1e40af;
        }

        .tag-treatment {
            background: #ede9fe;
            color: #5b21b6;
        }

        .tag-env {
            background: #ccfbf1;
            color: #0f766e;
        }

        .tag-location {
            background: #e0e7ff;
            color: #3730a3;
        }

        .tag-component {
            background: #f0fdf4;
            color: #166534;
        }

        .tag-complex {
            background: #faf5ff;
            color: #7e22ce;
        }

        .tag-bio {
            background: #fef3c7;
            color: #92400e;
        }

        .tag-modifier {
            background: #fee2e2;
            color: #991b1b;
            text-transform: uppercase;
            letter-spacing: 0.02em;
        }

        .tag-parent {
            background: #e0e7ff;
            color: #3730a3;
        }

        .tag-classification {
            background: #fef3c7;
            color: #92400e;
        }

        .tag-mechanistic {
            background: #dbeafe;
            color: #1e40af;
        }

        .linkout {
            color: inherit;
            margin-left: 6px;
            font-size: 0.75rem;
            text-decoration: none;
            border-bottom: 1px dotted rgba(0, 0, 0, 0.2);
        }

        .classification-category {
            font-size: 0.75rem;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.05em;
            color: var(--text-muted);
            margin-bottom: 8px;
        }

        .mapping-section {
            margin-bottom: 16px;
        }

        .mapping-item {
            padding: 10px 12px;
            border: 1px solid #e2e8f0;
            border-radius: 8px;
            background: #ffffff;
            margin-bottom: 10px;
        }

        .mapping-title {
            font-size: 0.9rem;
            font-weight: 600;
            display: flex;
            flex-wrap: wrap;
            gap: 8px;
            align-items: baseline;
            margin-bottom: 6px;
        }

        .mapping-label {
            color: var(--text-muted);
            font-weight: 500;
        }

        .mapping-notes {
            font-size: 0.85rem;
            color: var(--text-muted);
            margin-top: 6px;
        }

        .mapping-tree {
            margin-top: 6px;
            font-size: 0.75rem;
            color: var(--text-muted);
            list-style: none;
            padding-left: 0;
        }

        .mapping-tree li {
            margin: 2px 0;
        }

        /* Evidence styling */
        .evidence-toggle {
            cursor: pointer;
            font-size: 0.8rem;
            color: var(--text-muted);
            margin-top: 10px;
            user-select: none;
        }

        .evidence-toggle:hover {
            color: var(--primary);
        }

        .evidence-list {
            margin-top: 10px;
            padding-left: 0;
        }

        .evidence-item {
            padding: 12px 14px;
            background: #f8fafc;
            border-radius: 8px;
            margin-bottom: 8px;
            border: 1px solid #e2e8f0;
            font-size: 0.9rem;
        }

        .evidence-header {
            display: flex;
            align-items: center;
            flex-wrap: wrap;
            gap: 8px;
        }

        .evidence-ref {
            font-weight: 600;
            color: var(--secondary);
        }

        .evidence-ref a {
            color: inherit;
            text-decoration: none;
        }

        .evidence-ref a:hover {
            text-decoration: underline;
        }

        .evidence-support {
            font-size: 0.7rem;
            padding: 2px 8px;
            border-radius: 4px;
            font-weight: 600;
            text-transform: uppercase;
            transition: transform 120ms ease, box-shadow 120ms ease;
        }

        .support-SUPPORT { background: #dcfce7; color: #166534; }
        .support-PARTIAL { background: #fef3c7; color: #92400e; }
        .support-REFUTE { background: #fee2e2; color: #991b1b; }
        .support-NO_EVIDENCE { background: #f1f5f9; color: #64748b; }
        .support-WRONG_STATEMENT { background: #fecaca; color: #7f1d1d; }

        .evidence-source {
            font-size: 0.7rem;
            padding: 2px 8px;
            border-radius: 4px;
            font-weight: 600;
            text-transform: uppercase;
            background: #e2e8f0;
            color: #334155;
            transition: transform 120ms ease, box-shadow 120ms ease;
        }

        .evidence-support:hover,
        .evidence-source:hover {
            transform: translateY(-1px);
            box-shadow: 0 4px 10px rgba(0,0,0,0.08);
        }

        .source-HUMAN_CLINICAL { background: #e0f2fe; color: #075985; }
        .source-MODEL_ORGANISM { background: #fef9c3; color: #854d0e; }
        .source-IN_VITRO { background: #ede9fe; color: #5b21b6; }
        .source-COMPUTATIONAL { background: #cffafe; color: #0e7490; }
        .source-OTHER { background: #e5e7eb; color: #374151; }

        .evidence-snippet {
            font-size: 0.85rem;
            color: var(--text-muted);
            margin-top: 8px;
            padding-left: 12px;
            border-left: 2px solid #cbd5e1;
            font-style: italic;
            line-height: 1.5;
        }

        .evidence-explanation {
            font-size: 0.85rem;
            color: var(--text);
            margin-top: 6px;
            line-height: 1.5;
        }

        .evidence-more {
            font-size: 0.8rem;
            color: var(--text-muted);
            margin-top: 6px;
            font-style: italic;
        }

        .findings-section {
            margin-top: 12px;
        }

        .findings-title {
            font-size: 0.75rem;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.04em;
            color: var(--text-muted);
            margin-bottom: 6px;
        }

        .finding-item {
            padding: 10px 12px;
            background: #f8fafc;
            border-radius: 8px;
            margin-bottom: 8px;
            border: 1px solid #e2e8f0;
            font-size: 0.9rem;
        }

        .finding-statement {
            font-weight: 600;
            color: var(--text);
            margin-bottom: 6px;
            line-height: 1.5;
        }

        .finding-supporting {
            font-size: 0.85rem;
            color: var(--text-muted);
            margin-top: 6px;
            padding-left: 12px;
            border-left: 2px solid #cbd5e1;
            font-style: italic;
            line-height: 1.5;
        }

        /* Item containers with evidence */
        .item-box {
            padding: 16px;
            border-radius: 10px;
            margin-bottom: 12px;
        }

        .item-name {
            font-weight: 600;
            margin-bottom: 6px;
        }

        .item-name-link {
            color: inherit;
            text-decoration: underline;
            text-underline-offset: 2px;
            text-decoration-thickness: 1px;
        }

        .item-name-link:hover {
            text-decoration-thickness: 2px;
        }

        .missing-disease-name {
            color: #991b1b;
            border-bottom: 1px dotted #dc2626;
        }

        .curation-gap-badge {
            display: inline-flex;
            align-items: center;
            margin-left: 8px;
            padding: 2px 8px;
            border-radius: 999px;
            font-size: 0.72rem;
            font-weight: 700;
            letter-spacing: 0.01em;
            text-transform: uppercase;
            background: #fef2f2;
            border: 1px solid #fecaca;
            color: #b91c1c;
            vertical-align: middle;
        }

        .missing-ontology-link {
            color: #b91c1c !important;
            text-decoration: underline dotted;
            text-underline-offset: 2px;
        }

        .dismech-inline-link {
            margin-left: 6px;
            font-size: 0.78rem;
            font-weight: 600;
            color: #0369a1;
            text-decoration: underline;
            text-underline-offset: 2px;
            text-decoration-thickness: 1px;
            white-space: nowrap;
        }

        .dismech-inline-link:hover {
            text-decoration-thickness: 2px;
        }

        .item-desc {
            font-size: 0.9rem;
            line-height: 1.6;
            margin-bottom: 8px;
        }

        .item-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 6px;
            margin-top: 8px;
        }

        /* Definitions */
        .definition-box {
            background: #ecfeff;
            border-left: 4px solid #0ea5e9;
        }
        .definition-box .item-name { color: #0c4a6e; }
        .definition-box .item-desc { color: #075985; }

        /* Inheritance */
        .inheritance-box {
            background: #fef9c3;
            border-left: 4px solid #ca8a04;
        }
        .inheritance-box .item-name { color: #92400e; }
        .inheritance-box .item-desc { color: #92400e; }

        .criteria-block {
            margin-top: 12px;
            padding: 12px;
            border-radius: 8px;
            border: 1px solid #bae6fd;
            background: rgba(255, 255, 255, 0.7);
        }

        .criteria-title {
            font-weight: 600;
            color: #0c4a6e;
            margin-bottom: 6px;
        }

        .criteria-meta {
            font-size: 0.8rem;
            color: var(--text-muted);
            margin-bottom: 8px;
        }

        .criteria-header {
            font-size: 0.75rem;
            text-transform: uppercase;
            letter-spacing: 0.04em;
            color: #0284c7;
            margin-top: 8px;
        }

        .criteria-list {
            margin-left: 18px;
            font-size: 0.9rem;
            line-height: 1.5;
            color: #0f172a;
        }

        .criteria-list li {
            margin-bottom: 6px;
        }

        .criteria-detail {
            display: block;
            font-size: 0.85rem;
            color: var(--text-muted);
        }

        /* Pathophysiology */
        .pathophys-box {
            background: linear-gradient(135deg, #fef3c7 0%, #fef9c3 100%);
            border-left: 4px solid var(--accent-orange);
        }
        .pathophys-box .item-name { color: #92400e; }
        .pathophys-box .item-desc { color: #78350f; }

        /* Histopathology */
        .histopathology-box {
            background: #fff7ed;
            border-left: 4px solid #fb923c;
        }
        .histopathology-box .item-name { color: #9a3412; }
        .histopathology-box .item-desc { color: #c2410c; }

        .histopathology-freq {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #ffedd5;
            color: #c2410c;
        }

        /* Phenotypes */
        .phenotype-box {
            background: #f0fdf4;
            border-left: 4px solid #22c55e;
        }
        .phenotype-box .item-name { color: #166534; }
        .phenotype-box .item-desc { color: #15803d; }

        .phenotype-freq {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #dcfce7;
            color: #15803d;
        }

        .phenotype-category {
            font-size: 0.75rem;
            color: #4ade80;
        }

        .phenotype-id a {
            font-size: 0.8rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .phenotype-id a:hover {
            text-decoration: underline;
        }

        /* Phenotype TOC strip */
        .pheno-toc {
            display: flex;
            flex-wrap: wrap;
            gap: 6px;
            padding: 10px 0 6px 0;
            border-bottom: 1px solid #e2e8f0;
            margin-bottom: 4px;
        }

        .pheno-toc-pill {
            display: inline-block;
            font-size: 0.78rem;
            padding: 3px 10px;
            border-radius: 12px;
            background: #dcfce7;
            color: #166534;
            text-decoration: none;
            cursor: pointer;
            white-space: nowrap;
            transition: background 0.15s;
        }

        .pheno-toc-pill:hover {
            background: #bbf7d0;
        }

        .pheno-toc-pill .pill-count {
            font-weight: 600;
            margin-left: 2px;
        }

        .pheno-toggle-all {
            font-size: 0.78rem;
            color: #16a34a;
            cursor: pointer;
            background: none;
            border: 1px solid #bbf7d0;
            border-radius: 6px;
            padding: 3px 10px;
            margin-left: auto;
            white-space: nowrap;
            transition: background 0.15s;
        }

        .pheno-toggle-all:hover {
            background: #f0fdf4;
        }

        /* Collapsible category groups */
        .phenotype-category-group {
            margin-bottom: 2px;
        }

        .phenotype-category-group summary {
            font-size: 0.85rem;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.04em;
            color: #16a34a;
            margin: 0;
            padding: 10px 0 6px 0;
            border-bottom: 1px solid #bbf7d0;
            cursor: pointer;
            list-style: none;
            display: flex;
            align-items: center;
            gap: 6px;
        }

        .phenotype-category-group summary::-webkit-details-marker {
            display: none;
        }

        .phenotype-category-group summary .chevron {
            display: inline-block;
            width: 16px;
            height: 16px;
            transition: transform 0.15s;
            flex-shrink: 0;
        }

        .phenotype-category-group[open] summary .chevron {
            transform: rotate(90deg);
        }

        .phenotype-category-group summary .cat-count {
            font-size: 0.75rem;
            font-weight: 400;
            color: #15803d;
            background: #dcfce7;
            padding: 1px 7px;
            border-radius: 8px;
        }

        /* Phenotype Contexts */
        .phenotype-contexts {
            margin-top: 10px;
        }

        .phenotype-contexts-toggle {
            font-size: 0.8rem;
            color: var(--text-muted);
            cursor: pointer;
            user-select: none;
        }

        .phenotype-contexts-toggle:hover {
            color: var(--primary);
        }

        .context-card {
            padding: 10px 14px;
            margin-top: 8px;
            border-radius: 8px;
            background: #ecfdf5;
            border: 1px solid #a7f3d0;
            font-size: 0.88rem;
        }

        .context-header {
            display: flex;
            flex-wrap: wrap;
            align-items: center;
            gap: 6px;
            margin-bottom: 6px;
        }

        .context-label {
            font-size: 0.72rem;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.04em;
            padding: 2px 8px;
            border-radius: 4px;
        }

        .context-label-genetic {
            background: #dbeafe;
            color: #1e40af;
        }

        .context-label-sex {
            background: #fce7f3;
            color: #9d174d;
        }

        .context-label-population {
            background: #fef3c7;
            color: #92400e;
        }

        .context-label-age {
            background: #e0e7ff;
            color: #3730a3;
        }

        .context-label-subtype {
            background: #ede9fe;
            color: #5b21b6;
        }

        .context-label-frequency {
            background: #dcfce7;
            color: #166534;
        }

        .context-gene-list {
            display: flex;
            flex-wrap: wrap;
            gap: 4px;
            margin: 4px 0;
        }

        .context-gene-tag {
            font-size: 0.78rem;
            font-weight: 600;
            padding: 1px 8px;
            border-radius: 4px;
            background: #bfdbfe;
            color: #1e3a8a;
        }

        .context-detail {
            font-size: 0.84rem;
            color: #065f46;
            line-height: 1.5;
        }

        .context-detail strong {
            color: #047857;
        }

        .context-freq {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #bbf7d0;
            color: #14532d;
            font-weight: 600;
        }

        .context-onset {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #e0e7ff;
            color: #3730a3;
        }

        .context-severity {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #fef3c7;
            color: #92400e;
        }

        .context-notes {
            font-size: 0.84rem;
            color: #065f46;
            margin-top: 4px;
            line-height: 1.5;
        }

        /* Genetic */
        .genetic-box {
            background: #eff6ff;
            border-left: 4px solid #3b82f6;
        }
        .genetic-box .item-name { color: #1e40af; }
        .genetic-box .item-desc { color: #2563eb; }

        /* Treatment */
        .treatment-box {
            background: #faf5ff;
            border-left: 4px solid #8b5cf6;
        }
        .treatment-box .item-name { color: #5b21b6; }
        .treatment-box .item-desc { color: #7c3aed; }

        /* Environmental */
        .environmental-box {
            background: #f0fdfa;
            border-left: 4px solid #14b8a6;
        }
        .environmental-box .item-name { color: #0f766e; }
        .environmental-box .item-desc { color: #0d9488; }

        /* Biochemical */
        .biochemical-box {
            background: #fffbeb;
            border-left: 4px solid #f59e0b;
        }
        .biochemical-box .item-name { color: #92400e; }
        .biochemical-box .item-desc { color: #b45309; }

        /* Differential Diagnoses */
        .differential-box {
            background: #fef2f2;
            border-left: 4px solid #dc2626;
        }
        .differential-box .item-name { color: #7f1d1d; }
        .differential-box .item-desc { color: #b91c1c; }

        .differential-similarities {
            background: #fee2e2;
            border-left: 2px solid #dc2626;
            padding: 10px 12px;
            border-radius: 6px;
            margin: 8px 0;
            font-size: 0.9rem;
        }

        .differential-distinctions {
            background: #dcfce7;
            border-left: 2px solid #16a34a;
            padding: 10px 12px;
            border-radius: 6px;
            margin: 8px 0;
            font-size: 0.9rem;
        }

        .differential-similarities strong,
        .differential-distinctions strong {
            display: block;
            margin-bottom: 6px;
            font-size: 0.85rem;
            text-transform: uppercase;
            letter-spacing: 0.05em;
        }

        .differential-similarities ul,
        .differential-distinctions ul {
            margin-left: 16px;
            line-height: 1.6;
        }

        .differential-similarities li,
        .differential-distinctions li {
            margin: 4px 0;
            font-size: 0.9rem;
        }

        /* Datasets */
        .dataset-box {
            background: #f0f9ff;
            border-left: 4px solid #0284c7;
        }
        .dataset-box .item-name { color: #0c4a6e; }
        .dataset-box .item-desc { color: #0369a1; }

        .tag-dataset {
            background: #e0f2fe;
            color: #0369a1;
        }

        .tag-organism {
            background: #fae8ff;
            color: #a21caf;
        }

        .tag-datatype {
            background: #dbeafe;
            color: #1d4ed8;
        }

        /* Clinical Trials */
        .clinical-trial-box {
            background: #f5f3ff;
            border-left: 4px solid #a855f7;
        }
        .clinical-trial-box .item-name { color: #6b21a8; }
        .clinical-trial-box .item-desc { color: #7e22ce; }

        .tag-phase {
            background: #ede9fe;
            color: #6b21a8;
        }

        .tag-status {
            background: #fce7f3;
            color: #9d174d;
        }

        .trial-nct a {
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .trial-nct a:hover {
            text-decoration: underline;
        }

        .dataset-accession a {
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .dataset-accession a:hover {
            text-decoration: underline;
        }

        /* Subtypes */
        .subtype-box {
            background: #eef2ff;
            border-left: 4px solid var(--secondary);
        }
        .subtype-box .item-name { color: #3730a3; }
        .subtype-box .item-desc { color: #4f46e5; }
        .classification-header {
            font-size: 1rem;
            font-weight: 600;
            color: #4338ca;
            margin: 1.2rem 0 0.5rem 0;
            padding-bottom: 0.3rem;
            border-bottom: 2px solid #c7d2fe;
            text-transform: capitalize;
        }
        .subtype-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 0.4rem;
            margin: 0.3rem 0;
        }
        .subtype-freq-badge {
            background: #dbeafe;
            color: #1e40af;
            padding: 0.15rem 0.5rem;
            border-radius: 9999px;
            font-size: 0.8rem;
            font-weight: 500;
        }
        .subtype-gene-tag {
            background: #fef3c7;
            color: #92400e;
            padding: 0.15rem 0.5rem;
            border-radius: 9999px;
            font-size: 0.8rem;
            font-weight: 500;
        }
        .subtype-inheritance-tag {
            background: #ede9fe;
            color: #5b21b6;
            padding: 0.15rem 0.5rem;
            border-radius: 9999px;
            font-size: 0.8rem;
            font-weight: 500;
        }
        .subtype-term-link {
            font-size: 0.8rem;
            color: #6366f1;
            text-decoration: none;
        }
        .subtype-term-link:hover { text-decoration: underline; }
        .subtype-children {
            margin: 0.4rem 0 0.2rem 1rem;
            padding: 0;
            list-style: none;
        }
        .subtype-children li {
            font-size: 0.85rem;
            color: #4338ca;
            padding: 0.1rem 0;
        }
        .subtype-children li::before {
            content: "â†³ ";
            color: #a5b4fc;
        }

        /* Stats bar */
        .stats-bar {
            display: flex;
            gap: 24px;
            padding: 20px 24px;
            background: var(--card-bg);
            border-radius: 12px;
            border: 1px solid var(--border);
            margin-bottom: 24px;
            flex-wrap: wrap;
        }

        .stat-item {
            text-align: center;
        }

        .stat-link {
            text-decoration: none;
            color: inherit;
        }

        .stat-value {
            font-size: 1.5rem;
            font-weight: 700;
            color: var(--primary);
        }

        .stat-label {
            font-size: 0.8rem;
            color: var(--text-muted);
            text-transform: uppercase;
            letter-spacing: 0.05em;
        }

        /* YAML preview */
        .yaml-preview {
            background: #1e293b;
            color: #e2e8f0;
            padding: 20px;
            border-radius: 8px;
            overflow-x: auto;
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            line-height: 1.5;
            max-height: 400px;
            overflow-y: auto;
        }

        .yaml-content {
            display: none;
        }

        .yaml-content.show {
            display: block;
        }

        /* Footer */
        .page-footer {
            margin-top: 40px;
            padding-top: 20px;
            border-top: 1px solid var(--border);
            text-align: center;
            color: var(--text-muted);
            font-size: 0.85rem;
        }

        .page-footer a {
            color: var(--primary);
            text-decoration: none;
        }

        .page-footer a:hover {
            text-decoration: underline;
        }

        /* Responsive */
        @media (max-width: 768px) {
            .page-header h1 { font-size: 1.6rem; }
            .stats-bar { gap: 16px; }
            .section-grid { grid-template-columns: 1fr; }
        }
        /* Mermaid graph */
        .mermaid-container {
            text-align: center;
            margin: 20px 0;
            padding: 20px;
            background: white;
            border-radius: 8px;
            border: 1px solid var(--border);
            overflow-x: auto;
        }

        .mermaid svg {
            max-width: 100%;
            height: auto;
        }

        .graph-warning {
            background: #fef3c7;
            border: 1px solid #f59e0b;
            border-radius: 8px;
            padding: 12px 16px;
            margin-bottom: 16px;
            font-size: 0.85rem;
            color: #92400e;
        }

        .graph-warning strong {
            display: block;
            margin-bottom: 4px;
        }

        .graph-warning ul {
            margin: 8px 0 0 20px;
            padding: 0;
        }

        .graph-warning li {
            margin: 4px 0;
        }
    </style>
    <script src="https://cdn.jsdelivr.net/npm/mermaid@10/dist/mermaid.min.js"></script>
    <script>
        mermaid.initialize({
            startOnLoad: true,
            theme: 'default',
            flowchart: {
                htmlLabels: true,
                curve: 'basis'
            }
        });
    </script>
</head>
<body>
    <div class="notice-banner" role="button" tabindex="0">This resource is in its pre-alpha development stage. Content is actively being curated and may be incomplete or subject to change.</div>
    

    

    
    

    
    

    

    

    

    

    

    <div class="container">
        <nav class="breadcrumb">
            <a href="../../app/index.html">Browse All</a>
            <span> / </span>
            <span>Glutaryl-CoA Dehydrogenase Deficiency</span>
        </nav>

        <header class="page-header">
            <h1>Glutaryl-CoA Dehydrogenase Deficiency</h1>
            <div class="header-meta">
                
                <span class="badge badge-category">Mendelian</span>
                
                
                <span class="badge badge-mondo">
                    <a href="http://purl.obolibrary.org/obo/MONDO_0009281" target="_blank">
                        MONDO:0009281
                    </a>
                </span>
                
                
                <span class="badge badge-category" style="background: rgba(255,255,255,0.1);">Organic Acidemia</span>
                
                <span class="badge badge-category" style="background: rgba(255,255,255,0.1);">Inborn Error of Metabolism</span>
                
            </div>
            
            <p style="margin-top: 16px; font-size: 1rem; line-height: 1.6; opacity: 0.95; position: relative;">
                Glutaryl-CoA dehydrogenase deficiency (historically termed glutaric aciduria type 1, GA1) is a rare autosomal recessive neurometabolic disorder caused by deficiency of glutaryl-CoA dehydrogenase (GCDH), which catalyzes the final step of lysine, hydroxylysine, and tryptophan catabolism. GCDH deficiency leads to accumulation of neurotoxic metabolites glutaric acid (GA), 3-hydroxyglutaric acid (3-OH-GA), and glutarylcarnitine (C5DC). Untreated disease ranges from infantile-onset to later-onset forms (after age six years). Affected individuals are at highest risk for acute encephalopathic crises in early childhood (especially ages 3-36 months), often triggered by catabolic stress, which cause irreversible bilateral striatal necrosis and a complex dystonic movement disorder. Early diagnosis through newborn screening and adherence to metabolic treatment including lysine-restricted diet, carnitine supplementation, and emergency management during intercurrent illness can prevent striatal injury in the majority of patients. Even in treated cohorts, long-term surveillance is important, including attention to possible renal complications in adolescents and adults.

            </p>
            
        </header>

        <!-- Stats bar -->
        
        
        
        
        
        
        
        
        
        
        
        
        
        <div class="stats-bar">
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Mappings</div>
            </div>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Definitions</div>
            </div>
            
            
            <a class="stat-link" href="#inheritance">
            <div class="stat-item">
                <div class="stat-value">1</div>
                <div class="stat-label">Inheritance</div>
            </div>
            </a>
            
            
            <a class="stat-link" href="#pathophysiology">
            <div class="stat-item">
                <div class="stat-value">5</div>
                <div class="stat-label">Pathophysiology</div>
            </div>
            </a>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Histopathology</div>
            </div>
            
            
            <a class="stat-link" href="#phenotypes">
            <div class="stat-item">
                <div class="stat-value">11</div>
                <div class="stat-label">Phenotypes</div>
            </div>
            </a>
            
            
            <a class="stat-link" href="#genetic">
            <div class="stat-item">
                <div class="stat-value">1</div>
                <div class="stat-label">Genes</div>
            </div>
            </a>
            
            
            <a class="stat-link" href="#treatments">
            <div class="stat-item">
                <div class="stat-value">7</div>
                <div class="stat-label">Treatments</div>
            </div>
            </a>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Subtypes</div>
            </div>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Differentials</div>
            </div>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Datasets</div>
            </div>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Trials</div>
            </div>
            
        </div>

        <!-- Classifications -->
        

        <!-- Mappings -->
        

        <!-- Definitions -->
        

        <!-- Inheritance -->
        
        <div class="card" id="inheritance">
            <div class="card-header">
                <div class="card-icon" style="background: #fef3c7; color: #92400e;">ðŸ‘ª</div>
                <h2 class="card-title">Inheritance</h2>
                <span class="card-count">1</span>
            </div>
            
            <div class="item-box inheritance-box">
                <div class="item-name">
                    Autosomal recessive
                    
                    <span class="phenotype-id">
                        <a href="http://purl.obolibrary.org/obo/HP_0000007" target="_blank">
                            HP:0000007
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Glutaryl-CoA dehydrogenase deficiency is inherited in an autosomal recessive pattern with complete penetrance for biochemical phenotype but variable expressivity for neurological outcome. Carrier frequency varies by population.
</div>
                
                
    
    
    <div class="item-meta">
        
        <span class="tag tag-classification">
            Autosomal recessive inheritance
        </span>
        
        
        
        
        
    </div>
    
    
    
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/39185018" target="_blank">PMID:39185018</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Sequencing results showed each case had compound heterozygous variants in GCDH(NM_000159.4)"</div>
                
                
                <div class="evidence-explanation">Demonstrates compound heterozygous inheritance pattern consistent with autosomal recessive transmission.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://bioregistry.io/url:https://www.ncbi.nlm.nih.gov/books/NBK546575/?report=printable" target="_blank">url:https://www.ncbi.nlm.nih.gov/books/NBK546575/?report=printable</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-OTHER">Other</span>
                    
                </div>
                
                <div class="evidence-snippet">"At conception, each sib of an affected individual has a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier."</div>
                
                
                <div class="evidence-explanation">GeneReviews provides the canonical 25/50/25 autosomal recessive recurrence risk framework for GA1 families.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Subtypes -->
        

        <!-- Comorbidities -->
        

        <!-- Pathophysiology -->
        
        <div class="card" id="pathophysiology">
            <div class="card-header">
                <div class="card-icon" style="background: #fef3c7; color: #d97706;">âš™</div>
                <h2 class="card-title">Pathophysiology</h2>
                <span class="card-count">5</span>
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">GCDH protein misfolding</div>
                
                <div class="item-desc">Many GA1-causing missense variants lead to protein misfolding characterized by altered oligomerization, loss of protein stability and solubility, and increased susceptibility to aggregation. Reduced cellular activity is associated with loss of GCDH tetramerization. Variants closer to the N-terminus show more pronounced protein loss.
</div>
                
                
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-component">
                        mitochondrial matrix
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0005759" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
                </div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (3 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/37685964" target="_blank">PMID:37685964</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-IN_VITRO">In Vitro</span>
                    
                </div>
                
                <div class="evidence-snippet">"An altered oligomerization, loss of protein stability and solubility, as well as an augmented susceptibility to aggregation were observed."</div>
                
                
                <div class="evidence-explanation">Comprehensive biochemical characterization of GCDH misfolding across multiple variants.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/37685964" target="_blank">PMID:37685964</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-IN_VITRO">In Vitro</span>
                    
                </div>
                
                <div class="evidence-snippet">"The reduced cellular activity was associated with loss of tetramerization."</div>
                
                
                <div class="evidence-explanation">Loss of the native tetrameric assembly directly impairs enzymatic activity.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/37685964" target="_blank">PMID:37685964</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-IN_VITRO">In Vitro</span>
                    
                </div>
                
                <div class="evidence-snippet">"The broad panel of variant-mediated conformational changes of the GCDH protein supports the classification of GA1 as a protein-misfolding disorder."</div>
                
                
                <div class="evidence-explanation">Establishes GA1 as a protein misfolding disorder, opening avenues for pharmacological chaperone therapy.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">GCDH enzymatic deficiency and disrupted lysine catabolism</div>
                
                <div class="item-desc">Deficiency of glutaryl-CoA dehydrogenase (GCDH), the last enzyme of lysine catabolism, drives accumulation of glutaric acid (GA), 3-hydroxyglutaric acid (3-OH-GA), and glutarylcarnitine (C5DC).</div>
                
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        cellular amino acid catabolic process
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0009063" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-component">
                        mitochondrial matrix
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0005759" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
                    <span class="tag tag-component">
                        mitochondrion
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0005739" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
                </div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-location">
                        Liver
                        
                        <a href="http://purl.obolibrary.org/obo/UBERON_0002107" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
                    <span class="tag tag-location">
                        Striatum
                        
                        <a href="http://purl.obolibrary.org/obo/UBERON_0002435" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/37075130" target="_blank">PMID:37075130</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-MODEL_ORGANISM">Model Organism</span>
                    
                </div>
                
                <div class="evidence-snippet">"Glutaric aciduria type I (GA-1) is an inborn error of metabolism with a severe neurological phenotype caused by the deficiency of glutaryl-coenzyme A dehydrogenase (GCDH), the last enzyme of lysine catabolism."</div>
                
                
                <div class="evidence-explanation">Defines GA1 as GCDH deficiency at the terminal step of lysine catabolism.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/37685964" target="_blank">PMID:37685964</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-IN_VITRO">In Vitro</span>
                    
                </div>
                
                <div class="evidence-snippet">"Glutaric acidemia type 1 (GA1) is a neurotoxic metabolic disorder due to glutaryl-CoA dehydrogenase (GCDH) deficiency."</div>
                
                
                <div class="evidence-explanation">Supports the core enzymatic deficiency in GA1.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Brain exposure to toxic GA1 catabolites</div>
                
                <div class="item-desc">Brain tissue exposure to GA, 3-OH-GA, and related metabolites is the convergent toxic step in GA1. Competing origin models (intracerebral production versus hepatic source with transport) can be superimposed at this node.</div>
                
                
                
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-location">
                        Brain
                        
                        <a href="http://purl.obolibrary.org/obo/UBERON_0000955" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
                    <span class="tag tag-location">
                        Striatum
                        
                        <a href="http://purl.obolibrary.org/obo/UBERON_0002435" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/38983872" target="_blank">PMID:38983872</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-MODEL_ORGANISM">Model Organism</span>
                    
                </div>
                
                <div class="evidence-snippet">"a lack of treatment on an HLD triggers very high accumulation of glutaric acid, 3-hydroxyglutaric acid, and glutarylcarnitine in tissues, with about 60% death due to brain accumulation of toxic lysine metabolites."</div>
                
                
                <div class="evidence-explanation">Supports toxic metabolite accumulation in brain as a proximal injury step.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/37075130" target="_blank">PMID:37075130</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-MODEL_ORGANISM">Model Organism</span>
                    
                </div>
                
                <div class="evidence-snippet">"the characteristic brain and lethal phenotype of the GA-1 mouse model was rescued by two different liver-directed gene therapy approaches"</div>
                
                
                <div class="evidence-explanation">Rescue by liver-directed interventions supports metabolite burden as a causal brain-injury mediator.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Oxidative stress and neuroinflammation</div>
                
                <div class="item-desc">GCDH deficiency leads to disturbed redox homeostasis including increased lipid peroxidation, altered antioxidant defenses, and a pro-inflammatory response in the striatum and cerebral cortex. NF-kB pathway activation and microglial activation contribute to neuroinflammation. Mitochondrial dynamics are also disrupted with activated mitochondrial fission.
</div>
                
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        Response to oxidative stress
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0006979" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                    <span class="tag tag-bio">
                        Inflammatory response
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0006954" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-location">
                        Striatum
                        
                        <a href="http://purl.obolibrary.org/obo/UBERON_0002435" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
                    <span class="tag tag-location">
                        Cerebral cortex
                        
                        <a href="http://purl.obolibrary.org/obo/UBERON_0000956" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/35639256" target="_blank">PMID:35639256</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-MODEL_ORGANISM">Model Organism</span>
                    
                </div>
                
                <div class="evidence-snippet">"Increased lipid peroxidation and altered antioxidant defenses, including decreased concentrations of reduced glutathione and increased activities of superoxide dismutase, catalase, and glutathione transferase, were observed in the striatum and cerebral cortex of Gcdh-/- mice."</div>
                
                
                <div class="evidence-explanation">Demonstrates oxidative stress in striatum and cortex of GCDH-deficient mice.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/35639256" target="_blank">PMID:35639256</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-MODEL_ORGANISM">Model Organism</span>
                    
                </div>
                
                <div class="evidence-snippet">"the nuclear content of NF-ÎºB was increased, and the cytosolic content of IÎºBÎ± decreased in the striatum of the mutant animals, indicating a pro-inflammatory response."</div>
                
                
                <div class="evidence-explanation">Shows NF-kB-mediated neuroinflammation in the striatum.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Striatal vulnerability and encephalopathic crises</div>
                
                <div class="item-desc">The immature striatum is selectively vulnerable to damage during acute encephalopathic crises, typically occurring between ages 3 and 36 months. Catabolic stress from intercurrent illness triggers massive accumulation of neurotoxic metabolites, leading to bilateral striatal necrosis. This results in an irreversible complex dystonic movement disorder. The vulnerability window corresponds to a critical developmental period of striatal maturation.
</div>
                
                
                
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-location">
                        Striatum
                        
                        <a href="http://purl.obolibrary.org/obo/UBERON_0002435" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
                    <span class="tag tag-location">
                        Putamen
                        
                        <a href="http://purl.obolibrary.org/obo/UBERON_0001874" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
                    <span class="tag tag-location">
                        Caudate nucleus
                        
                        <a href="http://purl.obolibrary.org/obo/UBERON_0001873" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (3 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/35639256" target="_blank">PMID:35639256</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-MODEL_ORGANISM">Model Organism</span>
                    
                </div>
                
                <div class="evidence-snippet">"commonly manifest acute encephalopathy associated with severe striatum degeneration and progressive cortical and striatal injury"</div>
                
                
                <div class="evidence-explanation">Confirms striatal degeneration as a hallmark of GA1 neuropathology.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/37474264" target="_blank">PMID:37474264</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"The mean kurtosis values of the anterior and posterior putamen and Barry-Albright dystonia scores were most relevant (r = 0.721, 0.730, respectively)."</div>
                
                
                <div class="evidence-explanation">DKI imaging demonstrates that putamen microstructural damage correlates with dystonia severity.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://bioregistry.io/url:https://www.ncbi.nlm.nih.gov/books/NBK546575/?report=printable" target="_blank">url:https://www.ncbi.nlm.nih.gov/books/NBK546575/?report=printable</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-OTHER">Other</span>
                    
                </div>
                
                <div class="evidence-snippet">"crises result in acute bilateral striatal injury and subsequent complex movement disorders."</div>
                
                
                <div class="evidence-explanation">GeneReviews summarizes the canonical striatal injury to movement-disorder progression in untreated GA1.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Histopathology -->
        

        <!-- Causal Graph -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #e0e7ff; color: #4f46e5;">â¬¡</div>
                <h2 class="card-title">Causal Graph</h2>
            </div>
            
            <div class="mermaid-container">
                <pre class="mermaid">graph LR
    GCDH_enzymatic_deficiency_and_disrupted_lysine_catabolism[&#34;GCDH enzymatic deficiency and disrupted lysine catabolism&#34;]
    GCDH_protein_misfolding[&#34;GCDH protein misfolding&#34;]
    Oxidative_stress_and_neuroinflammation[&#34;Oxidative stress and neuroinflammation&#34;]
    Cerebral_white_matter_hyperintensity_on_MRI[&#34;Cerebral white matter hyperintensity on MRI&#34;]
    Striatal_vulnerability_and_encephalopathic_crises[&#34;Striatal vulnerability and encephalopathic crises&#34;]
    Dystonia[&#34;Dystonia&#34;]
    Frontotemporal_cerebral_atrophy[&#34;Frontotemporal cerebral atrophy&#34;]
    Brain_exposure_to_toxic_GA1_catabolites[&#34;Brain exposure to toxic GA1 catabolites&#34;]

    GCDH_protein_misfolding --&gt; GCDH_enzymatic_deficiency_and_disrupted_lysine_catabolism
    GCDH_enzymatic_deficiency_and_disrupted_lysine_catabolism --&gt; Brain_exposure_to_toxic_GA1_catabolites
    GCDH_enzymatic_deficiency_and_disrupted_lysine_catabolism --&gt; Brain_exposure_to_toxic_GA1_catabolites
    Brain_exposure_to_toxic_GA1_catabolites --&gt; Oxidative_stress_and_neuroinflammation
    Brain_exposure_to_toxic_GA1_catabolites --&gt; Striatal_vulnerability_and_encephalopathic_crises
    Oxidative_stress_and_neuroinflammation --&gt; Striatal_vulnerability_and_encephalopathic_crises
    Striatal_vulnerability_and_encephalopathic_crises --&gt; Dystonia
    Striatal_vulnerability_and_encephalopathic_crises --&gt; Frontotemporal_cerebral_atrophy
    Striatal_vulnerability_and_encephalopathic_crises --&gt; Cerebral_white_matter_hyperintensity_on_MRI

    style GCDH_enzymatic_deficiency_and_disrupted_lysine_catabolism fill:#dbeafe
    style GCDH_protein_misfolding fill:#dbeafe
    style Oxidative_stress_and_neuroinflammation fill:#dbeafe
    style Cerebral_white_matter_hyperintensity_on_MRI fill:#fef3c7
    style Striatal_vulnerability_and_encephalopathic_crises fill:#dbeafe
    style Dystonia fill:#fef3c7
    style Frontotemporal_cerebral_atrophy fill:#fef3c7
    style Brain_exposure_to_toxic_GA1_catabolites fill:#dbeafe</pre>
            </div>
        </div>
        

        <!-- Phenotypes -->
        
        <div class="card" id="phenotypes">
            <div class="card-header">
                <div class="card-icon" style="background: #dcfce7; color: #16a34a;">â—</div>
                <h2 class="card-title">Phenotypes</h2>
                <span class="card-count">11</span>
            </div>
            
            
            <div class="pheno-toc">
                
                <a class="pheno-toc-pill" data-target="pheno-cat-1">Head and Neck<span class="pill-count">(1)</span></a>
                
                <a class="pheno-toc-pill" data-target="pheno-cat-2">Metabolism<span class="pill-count">(1)</span></a>
                
                <a class="pheno-toc-pill" data-target="pheno-cat-3">Musculoskeletal<span class="pill-count">(1)</span></a>
                
                <a class="pheno-toc-pill" data-target="pheno-cat-4">Nervous System<span class="pill-count">(5)</span></a>
                
                <a class="pheno-toc-pill" data-target="pheno-cat-5">Other<span class="pill-count">(3)</span></a>
                
                <button class="pheno-toggle-all" id="phenoToggleAll">Expand all</button>
            </div>
            
            
            <details class="phenotype-category-group" id="pheno-cat-1">
                <summary>
                    <svg class="chevron" viewBox="0 0 16 16" fill="currentColor"><path d="M6 3l5 5-5 5V3z"/></svg>
                    Head and Neck
                    <span class="cat-count">1</span>
                </summary>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Macrocephaly
                        
                        <span class="phenotype-freq">VERY_FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0000256" target="_blank">
                                Macrocephaly
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0000256)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/39185018" target="_blank">PMID:39185018</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"The most common clinical manifestations included increased head circumference (77.19%)"</div>
                
                
                <div class="evidence-explanation">Literature review of Chinese GA1 patients shows macrocephaly in 77% of cases.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
            </details>
            
            <details class="phenotype-category-group" id="pheno-cat-2">
                <summary>
                    <svg class="chevron" viewBox="0 0 16 16" fill="currentColor"><path d="M6 3l5 5-5 5V3z"/></svg>
                    Metabolism
                    <span class="cat-count">1</span>
                </summary>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Metabolic acidosis
                        
                        <span class="phenotype-freq">VERY_RARE</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0001942" target="_blank">
                                Metabolic acidosis
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0001942)</span>
                        </span>
                        
                    </div>
                    
                    <div class="item-desc">GA1 differs from other organic acidurias in that encephalopathic crises are primarily neurological (striatal injury via excitotoxicity) rather than metabolic. Significant metabolic acidosis is uncommon.</div>
                    
                    
                    
    
    
                    
    
    
                </div>
                
            </details>
            
            <details class="phenotype-category-group" id="pheno-cat-3">
                <summary>
                    <svg class="chevron" viewBox="0 0 16 16" fill="currentColor"><path d="M6 3l5 5-5 5V3z"/></svg>
                    Musculoskeletal
                    <span class="cat-count">1</span>
                </summary>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Hypotonia
                        
                        <span class="phenotype-freq">FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0001252" target="_blank">
                                Hypotonia
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0001252)</span>
                        </span>
                        
                    </div>
                    
                    <div class="item-desc">Muscular hypotonia may be present in infancy as an early feature before the onset of dystonia. The Chinese literature review (PMID:39185018) identified motor developmental delay (65.15%) as the most common clinical manifestation, which often includes hypotonia in infants.</div>
                    
                    
                    
    
    
                    
    
    
                </div>
                
            </details>
            
            <details class="phenotype-category-group" id="pheno-cat-4">
                <summary>
                    <svg class="chevron" viewBox="0 0 16 16" fill="currentColor"><path d="M6 3l5 5-5 5V3z"/></svg>
                    Nervous System
                    <span class="cat-count">5</span>
                </summary>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Dystonia
                        
                        <span class="phenotype-freq">FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0001332" target="_blank">
                                Dystonia
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0001332)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/37474264" target="_blank">PMID:37474264</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"The diffusional kurtosis imaging metrics of the temporal lobe and basal ganglia were significantly correlated with the Barry-Albright dystonia scores."</div>
                
                
                <div class="evidence-explanation">DKI imaging demonstrates that basal ganglia microstructural changes correlate with dystonia severity scores.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Encephalopathy
                        
                        <span class="phenotype-freq">FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0001298" target="_blank">
                                Encephalopathy
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0001298)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/35639256" target="_blank">PMID:35639256</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-MODEL_ORGANISM">Model Organism</span>
                    
                </div>
                
                <div class="evidence-snippet">"commonly manifest acute encephalopathy associated with severe striatum degeneration"</div>
                
                
                <div class="evidence-explanation">Acute encephalopathy with striatal degeneration is the hallmark neurological event.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Seizures
                        
                        <span class="phenotype-freq">OCCASIONAL</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0001250" target="_blank">
                                Seizure
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0001250)</span>
                        </span>
                        
                    </div>
                    
                    <div class="item-desc">Seizures may occur during or following acute encephalopathic crises. EEG abnormalities were documented in 73.33% of Chinese GA1 patients (PMID:39185018), but EEG abnormalities do not equate to clinical seizures. Post-crisis epilepsy is a recognized sequela of striatal injury.</div>
                    
                    
                    
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Intellectual disability
                        
                        <span class="phenotype-freq">OCCASIONAL</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0001249" target="_blank">
                                Intellectual disability
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0001249)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/34588557" target="_blank">PMID:34588557</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"The biochemical high excreter phenotype is the major risk factor for cognitive impairment while cognitive functions do not appear to be impacted by current therapy and striatal damage."</div>
                
                
                <div class="evidence-explanation">Cognitive impairment is documented, particularly in high excreters, but median IQ of 87 is below-average rather than meeting the threshold for intellectual disability (IQ &lt;70). Most NBS-identified patients have mild cognitive effects rather than frank intellectual disability.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Cerebral white matter hyperintensity on MRI
                        
                        <span class="phenotype-freq">FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0030890" target="_blank">
                                Hyperintensity of cerebral white matter on MRI
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0030890)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/37474264" target="_blank">PMID:37474264</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Diffusional kurtosis imaging provides more comprehensive quantitative information regarding the gray and white matter micropathologic damage in glutaric aciduria type 1 than routine MR imaging scores."</div>
                
                
                <div class="evidence-explanation">Supports white matter microstructural injury in GA1, consistent with MRI white matter abnormalities.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
            </details>
            
            <details class="phenotype-category-group" id="pheno-cat-5">
                <summary>
                    <svg class="chevron" viewBox="0 0 16 16" fill="currentColor"><path d="M6 3l5 5-5 5V3z"/></svg>
                    Other
                    <span class="cat-count">3</span>
                </summary>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Motor delay
                        
                        <span class="phenotype-freq">VERY_FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0001270" target="_blank">
                                Motor delay
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0001270)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/39185018" target="_blank">PMID:39185018</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"motor developmental delay (65.15%)"</div>
                
                
                <div class="evidence-explanation">Literature review shows motor delay in 65% of GA1 patients.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Subdural hemorrhage
                        
                        <span class="phenotype-freq">OCCASIONAL</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0100309" target="_blank">
                                Subdural hemorrhage
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0100309)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/26219480" target="_blank">PMID:26219480</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Children with GA1 are reported to be predisposed to subdural hematoma (SDH) development due to stretching of cortical veins secondary to cerebral atrophy and expansion of CSF spaces."</div>
                
                
                <div class="evidence-explanation">Systematic review establishing the predisposition to SDH in GA1 and the need to distinguish from abusive head trauma.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/26219480" target="_blank">PMID:26219480</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"SDHs in 19/20 children with GA1 are accompanied by other brain abnormalities specific for GA1."</div>
                
                
                <div class="evidence-explanation">SDHs in GA1 almost always co-occur with other GA1-specific brain abnormalities, distinguishing them from abusive head trauma.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Frontotemporal cerebral atrophy
                        
                        <span class="phenotype-freq">FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0006892" target="_blank">
                                Frontotemporal cerebral atrophy
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0006892)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/26219480" target="_blank">PMID:26219480</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"cerebral atrophy and expansion of CSF spaces"</div>
                
                
                <div class="evidence-explanation">Cerebral atrophy with CSF space expansion is a recognized GA1 neuroimaging feature.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
            </details>
            
            <script>
            (function() {
                // TOC pill click: expand target group and scroll to it
                document.querySelectorAll('.pheno-toc-pill').forEach(function(pill) {
                    pill.addEventListener('click', function() {
                        var target = document.getElementById(pill.dataset.target);
                        if (target) {
                            target.open = true;
                            target.scrollIntoView({behavior: 'smooth', block: 'start'});
                        }
                    });
                });
                // Expand/collapse all toggle
                var btn = document.getElementById('phenoToggleAll');
                if (btn) {
                    btn.addEventListener('click', function() {
                        var groups = document.querySelectorAll('.phenotype-category-group');
                        var anyOpen = Array.from(groups).some(function(g) { return g.open; });
                        groups.forEach(function(g) { g.open = !anyOpen; });
                        btn.textContent = anyOpen ? 'Expand all' : 'Collapse all';
                    });
                }
            })();
            </script>
            
        </div>
        

        <!-- Genetic Associations -->
        
        <div class="card" id="genetic">
            <div class="card-header">
                <div class="card-icon" style="background: #dbeafe; color: #2563eb;">ðŸ§¬</div>
                <h2 class="card-title">Genetic Associations</h2>
                <span class="card-count">1</span>
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    GCDH variants causing glutaryl-CoA dehydrogenase deficiency
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(CAUSATIVE)</span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (3 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/39185018" target="_blank">PMID:39185018</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"67 distinct GCDH gene variants were identified among 73 patients, with missense variants being the most prevalent type (73.97%). The most frequent variant was c.1244-2 A &gt; C, observed in 17.12% of cases."</div>
                
                
                <div class="evidence-explanation">Comprehensive literature review of GCDH variant spectrum in Chinese GA1 patients.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/37685964" target="_blank">PMID:37685964</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-IN_VITRO">In Vitro</span>
                    
                </div>
                
                <div class="evidence-snippet">"The high number of missense variants associated with the disease and their impact on GCDH activity suggest that disturbed protein conformation can affect the biochemical phenotype."</div>
                
                
                <div class="evidence-explanation">Demonstrates that missense variants cause protein misfolding affecting biochemical phenotype.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/39185018" target="_blank">PMID:39185018</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"the majority of variant sites were located in exons 11 (25.37%) and 6 (22.39%)."</div>
                
                
                <div class="evidence-explanation">Identifies mutational hotspots in the GCDH gene.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Treatments -->
        
        <div class="card" id="treatments">
            <div class="card-header">
                <div class="card-icon" style="background: #ede9fe; color: #7c3aed;">ðŸ’Š</div>
                <h2 class="card-title">Treatments</h2>
                <span class="card-count">7</span>
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Lysine-restricted diet
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000088" target="_blank">
                            MAXO:0000088
                        </a>
                    </span>
                    
                </div>
                
                
                <div class="item-desc">A low-lysine or lysine-free diet is a cornerstone of GA1 metabolic treatment, aiming to reduce substrate availability for the deficient enzyme and decrease toxic metabolite production.
</div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/34588557" target="_blank">PMID:34588557</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Long-term neurologic outcome in GA1 involves both motor and cognitive functions. The biochemical high excreter phenotype is the major risk factor for cognitive impairment while cognitive functions do not appear to be impacted by current therapy and striatal damage."</div>
                
                
                <div class="evidence-explanation">Diet is standard of care but current therapy does not fully prevent cognitive impairment, particularly in high excreters.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://bioregistry.io/url:https://www.ncbi.nlm.nih.gov/books/NBK546575/?report=printable" target="_blank">url:https://www.ncbi.nlm.nih.gov/books/NBK546575/?report=printable</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-OTHER">Other</span>
                    
                </div>
                
                <div class="evidence-snippet">"Combined metabolic therapy includes low-lysine diet, carnitine supplementation, and emergency treatment during episodes with the goal of averting catabolism and minimizing CNS exposure to lysine and its toxic metabolic byproducts."</div>
                
                
                <div class="evidence-explanation">GeneReviews supports low-lysine diet as a core component of combined metabolic therapy aimed at reducing neurotoxic exposure.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Carnitine supplementation
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000058" target="_blank">
                            MAXO:0000058
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-meta">
                    <strong style="font-size: 0.8rem; color: #5b21b6;">Drug:</strong>
                    
                    <span class="tag tag-treatment">
                        carnitine
                        
                        <a href="http://purl.obolibrary.org/obo/CHEBI_17126" target="_blank" style="color: inherit; margin-left: 4px;">â†—</a>
                        
                    </span>
                    
                </div>
                
                
                <div class="item-desc">L-carnitine supplementation helps replenish secondary carnitine deficiency caused by urinary losses of glutarylcarnitine (C5DC) and supports metabolite detoxification.
</div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://bioregistry.io/url:https://www.ncbi.nlm.nih.gov/books/NBK546575/?report=printable" target="_blank">url:https://www.ncbi.nlm.nih.gov/books/NBK546575/?report=printable</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-OTHER">Other</span>
                    
                </div>
                
                <div class="evidence-snippet">"Combined metabolic therapy includes low-lysine diet, carnitine supplementation, and emergency treatment during episodes with the goal of averting catabolism and minimizing CNS exposure to lysine and its toxic metabolic byproducts."</div>
                
                
                <div class="evidence-explanation">GeneReviews identifies carnitine supplementation as part of standard combined metabolic treatment in GA1.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Emergency management during intercurrent illness
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000950" target="_blank">
                            MAXO:0000950
                        </a>
                    </span>
                    
                </div>
                
                
                <div class="item-desc">Aggressive emergency treatment during catabolic crises including high-energy intravenous glucose, prevention of catabolism, and monitoring to prevent acute striatal necrosis. The emergency protocol is critical during the vulnerability window (3-36 months of age).
</div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://bioregistry.io/url:https://www.ncbi.nlm.nih.gov/books/NBK546575/?report=printable" target="_blank">url:https://www.ncbi.nlm.nih.gov/books/NBK546575/?report=printable</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-OTHER">Other</span>
                    
                </div>
                
                <div class="evidence-snippet">"Combined metabolic therapy includes low-lysine diet, carnitine supplementation, and emergency treatment during episodes with the goal of averting catabolism and minimizing CNS exposure to lysine and its toxic metabolic byproducts."</div>
                
                
                <div class="evidence-explanation">GeneReviews supports emergency treatment during illness/stress as a core preventive strategy to reduce CNS toxic exposure.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://bioregistry.io/url:https://www.ncbi.nlm.nih.gov/books/NBK546575/?report=printable" target="_blank">url:https://www.ncbi.nlm.nih.gov/books/NBK546575/?report=printable</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-OTHER">Other</span>
                    
                </div>
                
                <div class="evidence-snippet">"&lt;i&gt;Agents/circumstances to avoid:&lt;/i&gt; Excessive dietary protein or protein malnutrition inducing catabolic state, prolonged fasting, catabolic illness (intercurrent infection; brief febrile illness post vaccination), inadequate caloric provision during other stressors (e.g., surgery or procedure..."</div>
                
                
                <div class="evidence-explanation">Defines key catabolic triggers that emergency protocols are designed to prevent or mitigate.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Newborn screening
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000124" target="_blank">
                            MAXO:0000124
                        </a>
                    </span>
                    
                </div>
                
                
                <div class="item-desc">Newborn screening (NBS) for GA1 using tandem mass spectrometry detection of elevated glutarylcarnitine (C5DC) enables presymptomatic diagnosis and early treatment initiation. Machine learning-based digital-tier strategies can reduce false-positive rates by over 90%.
</div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (3 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/39728403" target="_blank">PMID:39728403</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-COMPUTATIONAL">Computational</span>
                    
                </div>
                
                <div class="evidence-snippet">"the proposed digital-tier strategy based on logistic regression analysis, ridge regression, and support vector machine reduced the false-positive rate by over 90% compared to regular NBS while identifying all confirmed individuals with GA1 correctly."</div>
                
                
                <div class="evidence-explanation">Machine learning approaches can dramatically improve NBS specificity for GA1.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/39185018" target="_blank">PMID:39185018</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"38.36% were diagnosed through newborn screening"</div>
                
                
                <div class="evidence-explanation">NBS is an important diagnostic route for GA1 in China.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://bioregistry.io/url:https://www.ncbi.nlm.nih.gov/books/NBK546575/?report=printable" target="_blank">url:https://www.ncbi.nlm.nih.gov/books/NBK546575/?report=printable</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-OTHER">Other</span>
                    
                </div>
                
                <div class="evidence-snippet">"Because the early initiation of treatment dramatically improved the outcome for persons with GA-1, an international guideline group has recommended NBS."</div>
                
                
                <div class="evidence-explanation">GeneReviews directly supports NBS as outcome-improving and guideline-recommended in GA1.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Genetic counseling
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000079" target="_blank">
                            MAXO:0000079
                        </a>
                    </span>
                    
                </div>
                
                
                <div class="item-desc">Genetic counseling is essential for families with GA1 to explain the autosomal recessive inheritance pattern, recurrence risk, and options for prenatal diagnosis.
</div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (3 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/39185018" target="_blank">PMID:39185018</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"These findings facilitate the diagnosis and treatment of affected children and provide a basis for genetic counseling and prenatal diagnosis for their families."</div>
                
                
                <div class="evidence-explanation">Genetic variant identification enables genetic counseling and prenatal diagnosis.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://bioregistry.io/url:https://www.ncbi.nlm.nih.gov/books/NBK546575/?report=printable" target="_blank">url:https://www.ncbi.nlm.nih.gov/books/NBK546575/?report=printable</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-OTHER">Other</span>
                    
                </div>
                
                <div class="evidence-snippet">"&lt;i&gt;Evaluation of relatives at risk:&lt;/i&gt; Testing of all at-risk sibs of any age to allow for early diagnosis and treatment."</div>
                
                
                <div class="evidence-explanation">GeneReviews supports proactive testing of at-risk siblings as part of counseling and preventive care.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://bioregistry.io/url:https://www.ncbi.nlm.nih.gov/books/NBK546575/?report=printable" target="_blank">url:https://www.ncbi.nlm.nih.gov/books/NBK546575/?report=printable</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-OTHER">Other</span>
                    
                </div>
                
                <div class="evidence-snippet">"Once the &lt;i&gt;GCDH&lt;/i&gt; pathogenic variants in an affected family member are known, carrier testing for at-risk relatives, prenatal testing for a pregnancy at increased risk, and preimplantation genetic testing are possible."</div>
                
                
                <div class="evidence-explanation">Confirms scope of reproductive and familial counseling options once familial variants are identified.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Gene therapy (investigational)
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0001001" target="_blank">
                            MAXO:0001001
                        </a>
                    </span>
                    
                </div>
                
                
                <div class="item-desc">AAV-mediated gene therapy is under preclinical investigation for GA1. Both liver-directed approaches (replacing GCDH or deleting AASS to prevent lysine degradation flux) and systemic AAV9-GCDH delivery have shown efficacy in mouse models, restoring enzyme activity and preventing lysine diet-induced neuropathology.
</div>
                
                
                <div class="item-meta" style="margin-top: 8px;">
                    <strong style="font-size: 0.8rem; color: #7c3aed;">Mechanism Target:</strong>
                    
                    <div style="margin: 4px 0 4px 12px; font-size: 0.88rem;">
                        <span class="tag" style="background: #f3e8ff; color: #6b21a8; font-size: 0.8rem;">
                            RESTORES
                        </span>
                        <strong style="color: #5b21b6;">GCDH enzymatic deficiency and disrupted lysine catabolism</strong>
                        
                        <span style="color: #7c3aed;"> &mdash; AAV-mediated GCDH replacement restores GCDH expression and enzyme activity in target tissues.</span>
                        
                        
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/38983872" target="_blank">PMID:38983872</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-MODEL_ORGANISM">Model Organism</span>
                    
                </div>
                
                <div class="evidence-snippet">"Neonatal treatment with AAV-GCDH restores GCDH expression and enzyme activity in liver and striatum."</div>
                
                
                <div class="evidence-explanation">Supports restoration of the primary deficient enzymatic node by gene replacement therapy.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    </div>
                    
                    <div style="margin: 4px 0 4px 12px; font-size: 0.88rem;">
                        <span class="tag" style="background: #f3e8ff; color: #6b21a8; font-size: 0.8rem;">
                            INHIBITS
                        </span>
                        <strong style="color: #5b21b6;">Brain exposure to toxic GA1 catabolites</strong>
                        
                        <span style="color: #7c3aed;"> &mdash; Liver-directed gene therapy approaches reduce pathogenic brain metabolite burden.</span>
                        
                        
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/37075130" target="_blank">PMID:37075130</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-MODEL_ORGANISM">Model Organism</span>
                    
                </div>
                
                <div class="evidence-snippet">"the characteristic brain and lethal phenotype of the GA-1 mouse model was rescued by two different liver-directed gene therapy approaches"</div>
                
                
                <div class="evidence-explanation">Supports inhibition of the downstream toxic-catabolite brain exposure pathway.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    </div>
                    
                </div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (3 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/37075130" target="_blank">PMID:37075130</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-MODEL_ORGANISM">Model Organism</span>
                    
                </div>
                
                <div class="evidence-snippet">"the characteristic brain and lethal phenotype of the GA-1 mouse model was rescued by two different liver-directed gene therapy approaches: Using an adeno-associated virus, we replaced the defective Gcdh gene or we prevented flux through the lysine degradation pathway by CRISPR deletion of the..."</div>
                
                
                <div class="evidence-explanation">Preclinical evidence for two liver-directed gene therapy strategies for GA1.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/38983872" target="_blank">PMID:38983872</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-MODEL_ORGANISM">Model Organism</span>
                    
                </div>
                
                <div class="evidence-snippet">"Neonatal treatment with AAV-GCDH restores GCDH expression and enzyme activity in liver and striatum."</div>
                
                
                <div class="evidence-explanation">Systemic AAV9-GCDH delivery restores enzyme activity in target tissues.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/38983872" target="_blank">PMID:38983872</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-MODEL_ORGANISM">Model Organism</span>
                    
                </div>
                
                <div class="evidence-snippet">"AAV-GCDH significantly ameliorates the striatal neuropathology, minimizing neuronal dysfunction, gliosis, and alterations in myelination."</div>
                
                
                <div class="evidence-explanation">Gene therapy prevents striatal neuropathology in the GA1 mouse model.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Bezafibrate (investigational)
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000058" target="_blank">
                            MAXO:0000058
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-meta">
                    <strong style="font-size: 0.8rem; color: #5b21b6;">Drug:</strong>
                    
                    <span class="tag tag-treatment">
                        bezafibrate
                        
                        <a href="http://purl.obolibrary.org/obo/CHEBI_47612" target="_blank" style="color: inherit; margin-left: 4px;">â†—</a>
                        
                    </span>
                    
                </div>
                
                
                <div class="item-desc">The pan-PPAR agonist bezafibrate has shown neuroprotective effects in GCDH-deficient mice by normalizing oxidative stress and neuroinflammation in the striatum.
</div>
                
                
                <div class="item-meta" style="margin-top: 8px;">
                    <strong style="font-size: 0.8rem; color: #7c3aed;">Mechanism Target:</strong>
                    
                    <div style="margin: 4px 0 4px 12px; font-size: 0.88rem;">
                        <span class="tag" style="background: #f3e8ff; color: #6b21a8; font-size: 0.8rem;">
                            INHIBITS
                        </span>
                        <strong style="color: #5b21b6;">Oxidative stress and neuroinflammation</strong>
                        
                        <span style="color: #7c3aed;"> &mdash; Bezafibrate dampens oxidative and pro-inflammatory pathomechanisms in GCDH-deficient brain tissue.</span>
                        
                        
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/35639256" target="_blank">PMID:35639256</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-MODEL_ORGANISM">Model Organism</span>
                    
                </div>
                
                <div class="evidence-snippet">"in vivo treatment with the pan-PPAR agonist bezafibrate normalized these alterations."</div>
                
                
                <div class="evidence-explanation">Supports mechanistic inhibition/modulation of oxidative-inflammatory injury pathways.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    </div>
                    
                </div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/35639256" target="_blank">PMID:35639256</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-MODEL_ORGANISM">Model Organism</span>
                    
                </div>
                
                <div class="evidence-snippet">"in vivo treatment with the pan-PPAR agonist bezafibrate normalized these alterations."</div>
                
                
                <div class="evidence-explanation">Bezafibrate treatment normalized oxidative stress and inflammatory markers in GCDH-deficient mice.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/35639256" target="_blank">PMID:35639256</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-MODEL_ORGANISM">Model Organism</span>
                    
                </div>
                
                <div class="evidence-snippet">"bezafibrate should be tested as a potential adjuvant therapy for GA1."</div>
                
                
                <div class="evidence-explanation">Authors propose bezafibrate as a potential adjuvant therapy based on preclinical evidence.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Environmental Factors -->
        

        <!-- Biochemical Markers -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #fef3c7; color: #d97706;">ðŸ”¬</div>
                <h2 class="card-title">Biochemical Markers</h2>
                <span class="card-count">3</span>
            </div>
            
            <div class="item-box biochemical-box">
                <div class="item-name">
                    Elevated glutarylcarnitine (C5DC)
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(INCREASED)</span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/39185018" target="_blank">PMID:39185018</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"patients exhibited significant elevations in C5DC (98.51%) and C5DC/C8 (94.87%) in blood"</div>
                
                
                <div class="evidence-explanation">C5DC elevation in blood is near-universal in GA1 patients.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box biochemical-box">
                <div class="item-name">
                    Elevated glutaric acid in urine
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(INCREASED)</span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/39185018" target="_blank">PMID:39185018</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"GA (94.37%) and 3OHGA (69.39%) in urine"</div>
                
                
                <div class="evidence-explanation">Urinary GA elevation is present in the vast majority of GA1 patients.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/34588557" target="_blank">PMID:34588557</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"The biochemical high excreter phenotype is the major risk factor for cognitive impairment"</div>
                
                
                <div class="evidence-explanation">The high/low excreter distinction based on urinary GA levels is clinically significant for cognitive prognosis.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box biochemical-box">
                <div class="item-name">
                    Elevated 3-hydroxyglutaric acid in urine
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(INCREASED)</span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/39185018" target="_blank">PMID:39185018</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"GA (94.37%) and 3OHGA (69.39%) in urine"</div>
                
                
                <div class="evidence-explanation">Urinary 3-OH-GA elevation is present in about 69% of GA1 patients.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Differential Diagnoses -->
        

        <!-- Datasets -->
        

        <!-- Clinical Trials -->
        

        <!-- YAML Source -->
        <div class="card">
            <div class="card-header" style="cursor: pointer;" onclick="toggleYaml()">
                <div class="card-icon" style="background: #f1f5f9; color: #475569;">{ }</div>
                <h2 class="card-title">Source YAML</h2>
                <span class="card-count" id="yamlToggleText">click to show</span>
            </div>
            <div class="yaml-content" id="yamlContent">
                <pre class="yaml-preview">name: Glutaryl-CoA Dehydrogenase Deficiency
creation_date: &#39;2025-12-15T00:00:00Z&#39;
updated_date: &#39;2026-02-26T00:00:00Z&#39;
category: Mendelian
description: &#39;Glutaryl-CoA dehydrogenase deficiency (historically termed glutaric aciduria type 1, GA1) is a rare autosomal
  recessive neurometabolic disorder caused by deficiency of
  glutaryl-CoA dehydrogenase (GCDH), which catalyzes the final step of lysine, hydroxylysine, and tryptophan catabolism. GCDH
  deficiency leads to accumulation of neurotoxic metabolites glutaric acid (GA), 3-hydroxyglutaric acid (3-OH-GA), and glutarylcarnitine
  (C5DC). Untreated disease ranges from infantile-onset to later-onset forms (after age six years). Affected individuals are
  at highest risk for acute encephalopathic crises in early childhood (especially ages 3-36 months), often triggered
  by catabolic stress, which cause irreversible bilateral striatal necrosis and a complex dystonic movement disorder. Early
  diagnosis through newborn screening and adherence to metabolic treatment including lysine-restricted diet, carnitine supplementation,
  and emergency management during intercurrent illness can prevent striatal injury in the majority of patients. Even in treated
  cohorts, long-term surveillance is important, including attention to possible renal complications in adolescents and adults.

  &#39;
disease_term:
  preferred_term: glutaryl-CoA dehydrogenase deficiency
  term:
    id: MONDO:0009281
    label: glutaryl-CoA dehydrogenase deficiency
synonyms:
- glutaric aciduria type 1
- glutaric acidemia type 1
- GA1
parents:
- Organic Acidemia
- Inborn Error of Metabolism
references:
- reference: &#39;url:https://www.ncbi.nlm.nih.gov/books/NBK546575/?report=printable&#39;
  title: Glutaric Acidemia Type 1 - GeneReviewsÂ® - NCBI Bookshelf
  findings:
  - statement: NBS-identified and promptly treated individuals often avoid classic early striatal injury but still need long-term follow-up.
    supporting_text: In the era of newborn screening (NBS), the prompt initiation of treatment of asymptomatic infants detected by NBS means that most individuals who would have developed manifestations of either infantile-onset or later-onset GA-1 remain asymptomatic; however, they may be at increased risk for other manifestations (e.g., renal disease) that are becoming apparent as the understanding of the natural history of treated GA-1 continues to evolve.
    evidence:
    - reference: &#39;url:https://www.ncbi.nlm.nih.gov/books/NBK546575/?report=printable&#39;
      supports: SUPPORT
      evidence_source: OTHER
      snippet: In the era of newborn screening (NBS), the prompt initiation of treatment of asymptomatic infants detected by NBS means that most individuals who would have developed manifestations of either infantile-onset or later-onset GA-1 remain asymptomatic; however, they may be at increased risk for other manifestations (e.g., renal disease) that are becoming apparent as the understanding of the natural history of treated GA-1 continues to evolve.
      explanation: Supports continued surveillance, including renal monitoring, despite prevention of classic early neurologic crises.
  - statement: Standard care is combined metabolic therapy centered on lysine restriction, carnitine supplementation, and emergency illness management.
    supporting_text: Combined metabolic therapy includes low-lysine diet, carnitine supplementation, and emergency treatment during episodes with the goal of averting catabolism and minimizing CNS exposure to lysine and its toxic metabolic byproducts.
    evidence:
    - reference: &#39;url:https://www.ncbi.nlm.nih.gov/books/NBK546575/?report=printable&#39;
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Combined metabolic therapy includes low-lysine diet, carnitine supplementation, and emergency treatment during episodes with the goal of averting catabolism and minimizing CNS exposure to lysine and its toxic metabolic byproducts.
      explanation: Captures core treatment principles that structure current management recommendations.
  - statement: Catabolic triggers should be proactively avoided in GA1 management plans.
    supporting_text: &#34;Agents/circumstances to avoid: Excessive dietary protein or protein malnutrition inducing catabolic state, prolonged fasting, catabolic illness (intercurrent infection; brief febrile illness post vaccination), inadequate caloric provision during other stressors (e.g., surgery or procedure requiring fasting/anesthesia).&#34;
    evidence:
    - reference: &#39;url:https://www.ncbi.nlm.nih.gov/books/NBK546575/?report=printable&#39;
      supports: SUPPORT
      evidence_source: OTHER
      snippet: &#34;&lt;i&gt;Agents/circumstances to avoid:&lt;/i&gt; Excessive dietary protein or protein malnutrition inducing catabolic state, prolonged fasting, catabolic illness (intercurrent infection; brief febrile illness post vaccination), inadequate caloric provision during other stressors (e.g., surgery or procedure requiring fasting/anesthesia).&#34;
      explanation: Provides explicit avoidant-trigger guidance for sick-day and peri-procedural planning.
inheritance:
- name: Autosomal recessive
  inheritance_term:
    preferred_term: Autosomal recessive inheritance
    term:
      id: HP:0000007
      label: Autosomal recessive inheritance
  description: &#39;Glutaryl-CoA dehydrogenase deficiency is inherited in an autosomal recessive pattern with complete penetrance
    for biochemical phenotype but
    variable expressivity for neurological outcome. Carrier frequency varies by population.

    &#39;
  evidence:
  - reference: PMID:39185018
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Sequencing results showed each case had compound heterozygous variants in GCDH(NM_000159.4)
    explanation: Demonstrates compound heterozygous inheritance pattern consistent with autosomal recessive transmission.
  - reference: &#39;url:https://www.ncbi.nlm.nih.gov/books/NBK546575/?report=printable&#39;
    supports: SUPPORT
    evidence_source: OTHER
    snippet: At conception, each sib of an affected individual has a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier.
    explanation: GeneReviews provides the canonical 25/50/25 autosomal recessive recurrence risk framework for GA1 families.
mechanistic_hypotheses:
- hypothesis_group_id: canonical_ga1_metabolic_model
  hypothesis_label: Canonical GCDH Deficiency-Toxic Metabolite Model
  status: CANONICAL
  description: &gt;-
    Biallelic GCDH loss of function impairs lysine catabolism, resulting in accumulation of neurotoxic
    metabolites (GA, 3-OH-GA, C5DC) that drive striatal injury and dystonia, particularly during catabolic stress.
  evidence:
  - reference: PMID:37685964
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: Glutaric acidemia type 1 (GA1) is a neurotoxic metabolic disorder due to glutaryl-CoA dehydrogenase (GCDH) deficiency.
    explanation: Establishes the canonical disease mechanism linking GCDH deficiency to neurotoxic metabolic pathology.
- hypothesis_group_id: intracerebral_catabolite_origin_model
  hypothesis_label: Intracerebral Catabolite Origin Model
  status: ALTERNATIVE
  description: &gt;-
    Historical model proposing that toxic GA1 catabolites are generated predominantly within brain tissue
    and do not substantially cross the blood-brain barrier.
  evidence:
  - reference: PMID:37075130
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: Current literature suggests that toxic catabolites in the brain are produced locally and do not cross the blood-brain barrier.
    explanation: Captures the pre-existing local-production hypothesis as an alternative explanatory model.
- hypothesis_group_id: hepatic_catabolite_origin_model
  hypothesis_label: Hepatic Catabolite Origin and Transport Model
  status: EMERGING
  description: &gt;-
    Recent mouse data support predominant hepatic generation of toxic catabolites with subsequent transport to brain,
    revising prior assumptions of exclusively local brain production.
  evidence:
  - reference: PMID:37075130
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: In a series of experiments using knockout mice of the lysine catabolic pathway and liver cell transplantation, we uncovered that toxic GA-1 catabolites in the brain originated from the liver.
    explanation: Supports the liver-origin hypothesis as an emerging alternative to the intracerebral-origin model.
  - reference: PMID:37075130
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: Our findings question the current pathophysiological understanding of GA-1 and reveal a targeted therapy for this devastating disorder.
    explanation: Indicates that newer data challenge the prior model and motivate updated mechanistic framing.
pathophysiology:
- name: GCDH protein misfolding
  description: &#39;Many GA1-causing missense variants lead to protein misfolding characterized by altered oligomerization, loss
    of protein stability and solubility, and increased susceptibility to aggregation. Reduced cellular activity is associated
    with loss of GCDH tetramerization. Variants closer to the N-terminus show more pronounced protein loss.

    &#39;
  gene:
    preferred_term: GCDH
    description: Glutaryl-CoA dehydrogenase, whose missense variants lead to protein misfolding and loss of enzymatic activity.
    modifier: DECREASED
    term:
      id: hgnc:4189
      label: GCDH
  cellular_components:
  - preferred_term: mitochondrial matrix
    term:
      id: GO:0005759
      label: mitochondrial matrix
  evidence:
  - reference: PMID:37685964
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: An altered oligomerization, loss of protein stability and solubility, as well as an augmented susceptibility
      to aggregation were observed.
    explanation: Comprehensive biochemical characterization of GCDH misfolding across multiple variants.
  - reference: PMID:37685964
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: The reduced cellular activity was associated with loss of tetramerization.
    explanation: Loss of the native tetrameric assembly directly impairs enzymatic activity.
  - reference: PMID:37685964
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: The broad panel of variant-mediated conformational changes of the GCDH protein supports the classification of
      GA1 as a protein-misfolding disorder.
    explanation: Establishes GA1 as a protein misfolding disorder, opening avenues for pharmacological chaperone therapy.
  downstream:
  - target: GCDH enzymatic deficiency and disrupted lysine catabolism
    description: Loss of proper GCDH assembly decreases catalytic function in lysine degradation.
    hypothesis_groups:
    - canonical_ga1_metabolic_model
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:37685964
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: The reduced cellular activity was associated with loss of tetramerization.
      explanation: Links variant-driven misfolding directly to reduced enzymatic function.
- name: GCDH enzymatic deficiency and disrupted lysine catabolism
  description: &gt;-
    Deficiency of glutaryl-CoA dehydrogenase (GCDH), the last enzyme of lysine catabolism,
    drives accumulation of glutaric acid (GA), 3-hydroxyglutaric acid (3-OH-GA), and glutarylcarnitine (C5DC).
  gene:
    preferred_term: GCDH
    description: Glutaryl-CoA dehydrogenase, a mitochondrial matrix enzyme catalyzing oxidative decarboxylation of glutaryl-CoA.
    modifier: DECREASED
    term:
      id: hgnc:4189
      label: GCDH
  biological_processes:
  - preferred_term: cellular amino acid catabolic process
    term:
      id: GO:0009063
      label: cellular amino acid catabolic process
  cellular_components:
  - preferred_term: mitochondrial matrix
    term:
      id: GO:0005759
      label: mitochondrial matrix
  - preferred_term: mitochondrion
    term:
      id: GO:0005739
      label: mitochondrion
  locations:
  - preferred_term: Liver
    term:
      id: UBERON:0002107
      label: liver
  - preferred_term: Striatum
    term:
      id: UBERON:0002435
      label: striatum
  evidence:
  - reference: PMID:37075130
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: Glutaric aciduria type I (GA-1) is an inborn error of metabolism with a severe neurological phenotype caused by the deficiency of glutaryl-coenzyme A dehydrogenase (GCDH), the last enzyme of lysine catabolism.
    explanation: Defines GA1 as GCDH deficiency at the terminal step of lysine catabolism.
  - reference: PMID:37685964
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: Glutaric acidemia type 1 (GA1) is a neurotoxic metabolic disorder due to glutaryl-CoA dehydrogenase (GCDH) deficiency.
    explanation: Supports the core enzymatic deficiency in GA1.
  downstream:
  - target: Brain exposure to toxic GA1 catabolites
    description: Historical model proposes predominant local production of toxic catabolites within the brain.
    hypothesis_groups:
    - intracerebral_catabolite_origin_model
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - local lysine catabolic flux in brain tissue
    - limited blood-brain barrier transport
    evidence:
    - reference: PMID:37075130
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: Current literature suggests that toxic catabolites in the brain are produced locally and do not cross the blood-brain barrier.
      explanation: Encodes the prior intracerebral-origin hypothesis as one possible edge.
  - target: Brain exposure to toxic GA1 catabolites
    description: Alternative model proposes hepatic generation with transport of toxic catabolites to brain.
    hypothesis_groups:
    - hepatic_catabolite_origin_model
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - hepatic lysine catabolic flux
    - systemic transport to the brain
    evidence:
    - reference: PMID:37075130
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: In a series of experiments using knockout mice of the lysine catabolic pathway and liver cell transplantation, we uncovered that toxic GA-1 catabolites in the brain originated from the liver.
      explanation: Encodes the liver-origin hypothesis as an alternative edge to the same downstream node.
- name: Brain exposure to toxic GA1 catabolites
  description: &gt;-
    Brain tissue exposure to GA, 3-OH-GA, and related metabolites is the convergent toxic step in GA1.
    Competing origin models (intracerebral production versus hepatic source with transport) can be superimposed at this node.
  locations:
  - preferred_term: Brain
    term:
      id: UBERON:0000955
      label: brain
  - preferred_term: Striatum
    term:
      id: UBERON:0002435
      label: striatum
  evidence:
  - reference: PMID:38983872
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: a lack of treatment on an HLD triggers very high accumulation of glutaric acid, 3-hydroxyglutaric acid, and glutarylcarnitine in tissues, with about 60% death due to brain accumulation of toxic lysine metabolites.
    explanation: Supports toxic metabolite accumulation in brain as a proximal injury step.
  - reference: PMID:37075130
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: the characteristic brain and lethal phenotype of the GA-1 mouse model was rescued by two different liver-directed gene therapy approaches
    explanation: Rescue by liver-directed interventions supports metabolite burden as a causal brain-injury mediator.
  downstream:
  - target: Oxidative stress and neuroinflammation
    description: Toxic metabolite exposure perturbs redox balance and activates inflammatory pathways.
    hypothesis_groups:
    - canonical_ga1_metabolic_model
    - intracerebral_catabolite_origin_model
    - hepatic_catabolite_origin_model
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - mitochondrial dysfunction
    - lipid peroxidation
    - NF-kB pathway activation
    evidence:
    - reference: PMID:35639256
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: Increased lipid peroxidation and altered antioxidant defenses, including decreased concentrations of reduced glutathione and increased activities of superoxide dismutase, catalase, and glutathione transferase, were observed in the striatum and cerebral cortex ofÂ Gcdh-/-Â mice.
      explanation: Supports transition from metabolite burden to oxidative and inflammatory injury.
  - target: Striatal vulnerability and encephalopathic crises
    description: Toxic metabolite burden precipitates acute encephalopathy with selective striatal damage during stress.
    hypothesis_groups:
    - canonical_ga1_metabolic_model
    - intracerebral_catabolite_origin_model
    - hepatic_catabolite_origin_model
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:35639256
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: acute encephalopathy associated with severe striatum degeneration and progressive cortical and striatal injury
      explanation: Directly links brain metabolite toxicity to encephalopathy and striatal degeneration.
- name: Oxidative stress and neuroinflammation
  description: &#39;GCDH deficiency leads to disturbed redox homeostasis including increased lipid peroxidation, altered antioxidant
    defenses, and a pro-inflammatory response in the striatum and cerebral cortex. NF-kB pathway activation and microglial
    activation contribute to neuroinflammation. Mitochondrial dynamics are also disrupted with activated mitochondrial fission.

    &#39;
  biological_processes:
  - preferred_term: Response to oxidative stress
    term:
      id: GO:0006979
      label: response to oxidative stress
  - preferred_term: Inflammatory response
    term:
      id: GO:0006954
      label: inflammatory response
  locations:
  - preferred_term: Striatum
    term:
      id: UBERON:0002435
      label: striatum
  - preferred_term: Cerebral cortex
    term:
      id: UBERON:0000956
      label: cerebral cortex
  evidence:
  - reference: PMID:35639256
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: Increased lipid peroxidation and altered antioxidant defenses, including decreased concentrations of reduced glutathione and increased activities of superoxide dismutase, catalase, and glutathione transferase, were observed in the striatum and cerebral cortex of Gcdh-/- mice.
    explanation: Demonstrates oxidative stress in striatum and cortex of GCDH-deficient mice.
  - reference: PMID:35639256
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: the nuclear content of NF-ÎºB was increased, and the cytosolic content of IÎºBÎ± decreased in the striatum of the mutant animals, indicating a pro-inflammatory response.
    explanation: Shows NF-kB-mediated neuroinflammation in the striatum.
  downstream:
  - target: Striatal vulnerability and encephalopathic crises
    description: Redox and inflammatory injury amplify selective striatal degeneration.
    hypothesis_groups:
    - canonical_ga1_metabolic_model
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - microglial activation
    - ER-mitochondria crosstalk disturbance
    - activated mitochondrial fission
    evidence:
    - reference: PMID:35639256
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: We presume that some of these novel pathomechanisms may be involved in GA1 neuropathology
      explanation: Supports oxidative and inflammatory pathomechanisms as amplifiers of neuropathology.
- name: Striatal vulnerability and encephalopathic crises
  description: &#39;The immature striatum is selectively vulnerable to damage during acute encephalopathic crises, typically occurring
    between ages 3 and 36 months. Catabolic stress from intercurrent illness triggers massive accumulation of neurotoxic metabolites,
    leading to bilateral striatal necrosis. This results in an irreversible complex dystonic movement disorder. The vulnerability
    window corresponds to a critical developmental period of striatal maturation.

    &#39;
  locations:
  - preferred_term: Striatum
    term:
      id: UBERON:0002435
      label: striatum
  - preferred_term: Putamen
    term:
      id: UBERON:0001874
      label: putamen
  - preferred_term: Caudate nucleus
    term:
      id: UBERON:0001873
      label: caudate nucleus
  evidence:
  - reference: PMID:35639256
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: commonly manifest acute encephalopathy associated with severe striatum degeneration and progressive cortical and striatal injury
    explanation: Confirms striatal degeneration as a hallmark of GA1 neuropathology.
  - reference: PMID:37474264
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The mean kurtosis values of the anterior and posterior putamen and Barry-Albright dystonia scores were most relevant (r = 0.721, 0.730, respectively).
    explanation: DKI imaging demonstrates that putamen microstructural damage correlates with dystonia severity.
  - reference: &#39;url:https://www.ncbi.nlm.nih.gov/books/NBK546575/?report=printable&#39;
    supports: SUPPORT
    evidence_source: OTHER
    snippet: crises result in acute bilateral striatal injury and subsequent complex movement disorders.
    explanation: GeneReviews summarizes the canonical striatal injury to movement-disorder progression in untreated GA1.
  downstream:
  - target: Dystonia
    description: Bilateral striatal injury produces chronic dystonic movement disorder.
    hypothesis_groups:
    - canonical_ga1_metabolic_model
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:37474264
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: The diffusional kurtosis imaging metrics of the temporal lobe and basal ganglia were significantly correlated with the Barry-Albright dystonia scores.
      explanation: Supports a direct striatal injury to dystonia relationship.
  - target: Frontotemporal cerebral atrophy
    description: Progressive striatal/cortical injury contributes to chronic cerebral atrophic changes.
    hypothesis_groups:
    - canonical_ga1_metabolic_model
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - progressive cortical and striatal injury
    evidence:
    - reference: PMID:26219480
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: cerebral atrophy and expansion of CSF spaces
      explanation: Supports downstream cerebral atrophy after recurrent neurotoxic injury.
  - target: Cerebral white matter hyperintensity on MRI
    description: White-matter microstructural injury accompanies gray-matter basal ganglia pathology.
    hypothesis_groups:
    - canonical_ga1_metabolic_model
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - progressive cortical and striatal injury
    - white matter micropathologic damage
    evidence:
    - reference: PMID:37474264
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Diffusional kurtosis imaging provides more comprehensive quantitative information regarding the gray and white matter micropathologic damage in glutaric aciduria type 1 than routine MR imaging scores.
      explanation: Supports white matter injury as a downstream neuroimaging consequence.
phenotypes:
- name: Macrocephaly
  frequency: VERY_FREQUENT
  description: &#39;Increased head circumference is one of the most common clinical manifestations, present in approximately 77%
    of patients. Often the first clinical sign raising suspicion before screening results are available.

    &#39;
  phenotype_term:
    preferred_term: Macrocephaly
    term:
      id: HP:0000256
      label: Macrocephaly
  evidence:
  - reference: PMID:39185018
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The most common clinical manifestations included increased head circumference (77.19%)
    explanation: Literature review of Chinese GA1 patients shows macrocephaly in 77% of cases.
- name: Dystonia
  frequency: FREQUENT
  description: &#39;Complex dystonic movement disorder resulting from bilateral striatal injury during encephalopathic crises.
    Severity correlates with extent of putamen damage on neuroimaging.

    &#39;
  phenotype_term:
    preferred_term: Dystonia
    term:
      id: HP:0001332
      label: Dystonia
  evidence:
  - reference: PMID:37474264
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The diffusional kurtosis imaging metrics of the temporal lobe and basal ganglia were significantly correlated
      with the Barry-Albright dystonia scores.
    explanation: DKI imaging demonstrates that basal ganglia microstructural changes correlate with dystonia severity scores.
- name: Motor delay
  frequency: VERY_FREQUENT
  description: &#39;Developmental motor delay is common, present in approximately 65% of patients. May be evident before or after
    an encephalopathic crisis.

    &#39;
  phenotype_term:
    preferred_term: Motor delay
    term:
      id: HP:0001270
      label: Motor delay
  evidence:
  - reference: PMID:39185018
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: motor developmental delay (65.15%)
    explanation: Literature review shows motor delay in 65% of GA1 patients.
- name: Encephalopathy
  frequency: FREQUENT
  description: &#39;Acute encephalopathic crises typically occur between 3 and 36 months of age, often triggered by catabolic
    stress from febrile illness. These crises cause irreversible striatal injury if not prevented by emergency management.

    &#39;
  phenotype_term:
    preferred_term: Encephalopathy
    term:
      id: HP:0001298
      label: Encephalopathy
  evidence:
  - reference: PMID:35639256
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: commonly manifest acute encephalopathy associated with severe striatum degeneration
    explanation: Acute encephalopathy with striatal degeneration is the hallmark neurological event.
- name: Subdural hemorrhage
  frequency: OCCASIONAL
  description: &#39;Children with GA1 are predisposed to subdural hematoma development due to stretching of cortical veins secondary
    to cerebral atrophy and expansion of CSF spaces. SDH in GA1 must be distinguished from abusive head trauma.

    &#39;
  phenotype_term:
    preferred_term: Subdural hemorrhage
    term:
      id: HP:0100309
      label: Subdural hemorrhage
  evidence:
  - reference: PMID:26219480
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Children with GA1 are reported to be predisposed to subdural hematoma (SDH) development due to stretching of
      cortical veins secondary to cerebral atrophy and expansion of CSF spaces.
    explanation: Systematic review establishing the predisposition to SDH in GA1 and the need to distinguish from abusive
      head trauma.
  - reference: PMID:26219480
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: SDHs in 19/20 children with GA1 are accompanied by other brain abnormalities specific for GA1.
    explanation: SDHs in GA1 almost always co-occur with other GA1-specific brain abnormalities, distinguishing them from
      abusive head trauma.
- name: Metabolic acidosis
  frequency: VERY_RARE
  description: &gt;-
    Unlike other organic acidurias (e.g., propionic acidemia, methylmalonic acidemia), GA1 does not
    characteristically cause significant metabolic acidosis. Encephalopathic crises in GA1 are primarily
    neurological events (striatal necrosis) rather than metabolic acidosis episodes. Metabolic acidosis
    may occur rarely during severe intercurrent illness but is not a defining feature.
  phenotype_term:
    preferred_term: Metabolic acidosis
    term:
      id: HP:0001942
      label: Metabolic acidosis
  notes: &gt;-
    GA1 differs from other organic acidurias in that encephalopathic crises are primarily neurological
    (striatal injury via excitotoxicity) rather than metabolic. Significant metabolic acidosis is uncommon.
- name: Seizures
  frequency: OCCASIONAL
  description: Seizures may occur during or after encephalopathic crises.
  phenotype_term:
    preferred_term: Seizure
    term:
      id: HP:0001250
      label: Seizure
  notes: &gt;-
    Seizures may occur during or following acute encephalopathic crises. EEG abnormalities were documented
    in 73.33% of Chinese GA1 patients (PMID:39185018), but EEG abnormalities do not equate to clinical
    seizures. Post-crisis epilepsy is a recognized sequela of striatal injury.
- name: Intellectual disability
  frequency: OCCASIONAL
  description: &gt;-
    Cognitive performance is mildly reduced in GA1 patients identified by newborn screening, particularly
    in those with the biochemical high excreter phenotype (median IQ 84) compared to low excreters
    (median IQ 98). Most patients do not meet criteria for intellectual disability (IQ &lt;70) but
    have below-average cognitive function.
  phenotype_term:
    preferred_term: Intellectual disability
    term:
      id: HP:0001249
      label: Intellectual disability
  evidence:
  - reference: PMID:34588557
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: The biochemical high excreter phenotype is the major risk factor for cognitive impairment while
      cognitive functions do not appear to be impacted by current therapy and striatal damage.
    explanation: Cognitive impairment is documented, particularly in high excreters, but median IQ of 87 is
      below-average rather than meeting the threshold for intellectual disability (IQ &lt;70). Most
      NBS-identified patients have mild cognitive effects rather than frank intellectual disability.
- name: Hypotonia
  frequency: FREQUENT
  description: &#39;Muscular hypotonia may be present in infancy, particularly before the onset of dystonia.

    &#39;
  phenotype_term:
    preferred_term: Hypotonia
    term:
      id: HP:0001252
      label: Hypotonia
  notes: &gt;-
    Muscular hypotonia may be present in infancy as an early feature before the onset of dystonia.
    The Chinese literature review (PMID:39185018) identified motor developmental delay (65.15%)
    as the most common clinical manifestation, which often includes hypotonia in infants.
- name: Frontotemporal cerebral atrophy
  frequency: FREQUENT
  description: &#39;Frontotemporal atrophy with widened Sylvian fissures and expanded CSF spaces is a characteristic neuroimaging
    finding in GA1.

    &#39;
  phenotype_term:
    preferred_term: Frontotemporal cerebral atrophy
    term:
      id: HP:0006892
      label: Frontotemporal cerebral atrophy
  evidence:
  - reference: PMID:26219480
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: cerebral atrophy and expansion of CSF spaces
    explanation: Cerebral atrophy with CSF space expansion is a recognized GA1 neuroimaging feature.
- name: Cerebral white matter hyperintensity on MRI
  frequency: FREQUENT
  description: &#39;Abnormalities in white matter are detected on MRI in the majority of GA1 patients.

    &#39;
  phenotype_term:
    preferred_term: Hyperintensity of cerebral white matter on MRI
    term:
      id: HP:0030890
      label: Hyperintensity of cerebral white matter on MRI
  evidence:
  - reference: PMID:37474264
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Diffusional kurtosis imaging provides more comprehensive quantitative information regarding the gray and white matter micropathologic damage in glutaric aciduria type 1 than routine MR imaging scores.
    explanation: Supports white matter microstructural injury in GA1, consistent with MRI white matter abnormalities.
biochemical:
- name: Elevated glutarylcarnitine (C5DC)
  presence: INCREASED
  notes: &#39;C5DC is the primary newborn screening biomarker for GA1 detected by tandem mass spectrometry. Elevated in blood
    in approximately 98.5% of GA1 patients.

    &#39;
  evidence:
  - reference: PMID:39185018
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: patients exhibited significant elevations in C5DC (98.51%) and C5DC/C8 (94.87%) in blood
    explanation: C5DC elevation in blood is near-universal in GA1 patients.
- name: Elevated glutaric acid in urine
  presence: INCREASED
  notes: &#39;Glutaric acid is elevated in urine in approximately 94% of GA1 patients. The level of urinary GA excretion distinguishes
    high excreters from low excreters.

    &#39;
  evidence:
  - reference: PMID:39185018
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: GA (94.37%) and 3OHGA (69.39%) in urine
    explanation: Urinary GA elevation is present in the vast majority of GA1 patients.
  - reference: PMID:34588557
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The biochemical high excreter phenotype is the major risk factor for cognitive impairment
    explanation: The high/low excreter distinction based on urinary GA levels is clinically significant for cognitive prognosis.
- name: Elevated 3-hydroxyglutaric acid in urine
  presence: INCREASED
  notes: &#39;3-OH-GA is elevated in urine in approximately 69% of GA1 patients and is considered the most neurotoxic metabolite.

    &#39;
  evidence:
  - reference: PMID:39185018
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: GA (94.37%) and 3OHGA (69.39%) in urine
    explanation: Urinary 3-OH-GA elevation is present in about 69% of GA1 patients.
genetic:
- name: GCDH variants causing glutaryl-CoA dehydrogenase deficiency
  gene_term:
    preferred_term: GCDH
    term:
      id: hgnc:4189
      label: GCDH
  association: CAUSATIVE
  features: &#39;Biallelic pathogenic variants in the GCDH gene cause GA1. Over 200 pathogenic variants have been identified.
    Missense variants are the most prevalent type (approximately 74%). The most frequent variant in Chinese populations is
    c.1244-2A&gt;C. Most variant sites are located in exons 11 and 6. Genotype-phenotype correlations exist, with some variants
    associated with residual GCDH activity and the low excreter biochemical phenotype.

    &#39;
  evidence:
  - reference: PMID:39185018
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: 67 distinct GCDH gene variants were identified among 73 patients, with missense variants being the most prevalent
      type (73.97%). The most frequent variant was c.1244-2 A &gt; C, observed in 17.12% of cases.
    explanation: Comprehensive literature review of GCDH variant spectrum in Chinese GA1 patients.
  - reference: PMID:37685964
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: The high number of missense variants associated with the disease and their impact on GCDH activity suggest that
      disturbed protein conformation can affect the biochemical phenotype.
    explanation: Demonstrates that missense variants cause protein misfolding affecting biochemical phenotype.
  - reference: PMID:39185018
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: the majority of variant sites were located in exons 11 (25.37%) and 6 (22.39%).
    explanation: Identifies mutational hotspots in the GCDH gene.
treatments:
- name: Lysine-restricted diet
  description: &#39;A low-lysine or lysine-free diet is a cornerstone of GA1 metabolic treatment, aiming to reduce substrate availability
    for the deficient enzyme and decrease toxic metabolite production.

    &#39;
  treatment_term:
    preferred_term: dietary intervention
    term:
      id: MAXO:0000088
      label: dietary intervention
  evidence:
  - reference: PMID:34588557
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: Long-term neurologic outcome in GA1 involves both motor and cognitive functions. The biochemical high excreter
      phenotype is the major risk factor for cognitive impairment while cognitive functions do not appear to be impacted by
      current therapy and striatal damage.
    explanation: Diet is standard of care but current therapy does not fully prevent cognitive impairment, particularly in
      high excreters.
  - reference: &#39;url:https://www.ncbi.nlm.nih.gov/books/NBK546575/?report=printable&#39;
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Combined metabolic therapy includes low-lysine diet, carnitine supplementation, and emergency treatment during episodes with the goal of averting catabolism and minimizing CNS exposure to lysine and its toxic metabolic byproducts.
    explanation: GeneReviews supports low-lysine diet as a core component of combined metabolic therapy aimed at reducing neurotoxic exposure.
- name: Carnitine supplementation
  description: &#39;L-carnitine supplementation helps replenish secondary carnitine deficiency caused by urinary losses of glutarylcarnitine
    (C5DC) and supports metabolite detoxification.

    &#39;
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
    therapeutic_agent:
    - preferred_term: carnitine
      term:
        id: CHEBI:17126
        label: carnitine
  notes: &gt;-
    L-carnitine supplementation is recommended in international GA1 guidelines to replenish secondary
    carnitine deficiency caused by urinary losses of glutarylcarnitine (C5DC). Nearly all GA1 patients
    (98.51%) show elevated C5DC (PMID:39185018), reflecting ongoing carnitine conjugation and loss.
  evidence:
  - reference: &#39;url:https://www.ncbi.nlm.nih.gov/books/NBK546575/?report=printable&#39;
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Combined metabolic therapy includes low-lysine diet, carnitine supplementation, and emergency treatment during episodes with the goal of averting catabolism and minimizing CNS exposure to lysine and its toxic metabolic byproducts.
    explanation: GeneReviews identifies carnitine supplementation as part of standard combined metabolic treatment in GA1.
- name: Emergency management during intercurrent illness
  description: &#39;Aggressive emergency treatment during catabolic crises including high-energy intravenous glucose, prevention
    of catabolism, and monitoring to prevent acute striatal necrosis. The emergency protocol is critical during the vulnerability
    window (3-36 months of age).

    &#39;
  treatment_term:
    preferred_term: supportive care
    term:
      id: MAXO:0000950
      label: supportive care
  notes: &gt;-
    Aggressive emergency treatment during catabolic crises is a cornerstone of GA1 management per
    international guidelines. The German NBS follow-up cohort (PMID:34588557, n=107) demonstrates that
    early identification and treatment adherence are critical for outcomes.
  evidence:
  - reference: &#39;url:https://www.ncbi.nlm.nih.gov/books/NBK546575/?report=printable&#39;
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Combined metabolic therapy includes low-lysine diet, carnitine supplementation, and emergency treatment during episodes with the goal of averting catabolism and minimizing CNS exposure to lysine and its toxic metabolic byproducts.
    explanation: GeneReviews supports emergency treatment during illness/stress as a core preventive strategy to reduce CNS toxic exposure.
  - reference: &#39;url:https://www.ncbi.nlm.nih.gov/books/NBK546575/?report=printable&#39;
    supports: SUPPORT
    evidence_source: OTHER
    snippet: &#34;&lt;i&gt;Agents/circumstances to avoid:&lt;/i&gt; Excessive dietary protein or protein malnutrition inducing catabolic state, prolonged fasting, catabolic illness (intercurrent infection; brief febrile illness post vaccination), inadequate caloric provision during other stressors (e.g., surgery or procedure requiring fasting/anesthesia).&#34;
    explanation: Defines key catabolic triggers that emergency protocols are designed to prevent or mitigate.
- name: Newborn screening
  description: &#39;Newborn screening (NBS) for GA1 using tandem mass spectrometry detection of elevated glutarylcarnitine (C5DC)
    enables presymptomatic diagnosis and early treatment initiation. Machine learning-based digital-tier strategies can reduce
    false-positive rates by over 90%.

    &#39;
  treatment_term:
    preferred_term: disease screening
    term:
      id: MAXO:0000124
      label: disease screening
  evidence:
  - reference: PMID:39728403
    supports: SUPPORT
    evidence_source: COMPUTATIONAL
    snippet: the proposed digital-tier strategy based on logistic regression analysis, ridge regression, and support vector
      machine reduced the false-positive rate by over 90% compared to regular NBS while identifying all confirmed individuals
      with GA1 correctly.
    explanation: Machine learning approaches can dramatically improve NBS specificity for GA1.
  - reference: PMID:39185018
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: 38.36% were diagnosed through newborn screening
    explanation: NBS is an important diagnostic route for GA1 in China.
  - reference: &#39;url:https://www.ncbi.nlm.nih.gov/books/NBK546575/?report=printable&#39;
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Because the early initiation of treatment dramatically improved the outcome for persons with GA-1, an international guideline group has recommended NBS.
    explanation: GeneReviews directly supports NBS as outcome-improving and guideline-recommended in GA1.
- name: Genetic counseling
  description: &#39;Genetic counseling is essential for families with GA1 to explain the autosomal recessive inheritance pattern,
    recurrence risk, and options for prenatal diagnosis.

    &#39;
  treatment_term:
    preferred_term: genetic counseling
    term:
      id: MAXO:0000079
      label: genetic counseling
  evidence:
  - reference: PMID:39185018
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: These findings facilitate the diagnosis and treatment of affected children and provide a basis for genetic counseling
      and prenatal diagnosis for their families.
    explanation: Genetic variant identification enables genetic counseling and prenatal diagnosis.
  - reference: &#39;url:https://www.ncbi.nlm.nih.gov/books/NBK546575/?report=printable&#39;
    supports: SUPPORT
    evidence_source: OTHER
    snippet: &#34;&lt;i&gt;Evaluation of relatives at risk:&lt;/i&gt; Testing of all at-risk sibs of any age to allow for early diagnosis and treatment.&#34;
    explanation: GeneReviews supports proactive testing of at-risk siblings as part of counseling and preventive care.
  - reference: &#39;url:https://www.ncbi.nlm.nih.gov/books/NBK546575/?report=printable&#39;
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Once the &lt;i&gt;GCDH&lt;/i&gt; pathogenic variants in an affected family member are known, carrier testing for at-risk relatives, prenatal testing for a pregnancy at increased risk, and preimplantation genetic testing are possible.
    explanation: Confirms scope of reproductive and familial counseling options once familial variants are identified.
- name: Gene therapy (investigational)
  description: &#39;AAV-mediated gene therapy is under preclinical investigation for GA1. Both liver-directed approaches (replacing
    GCDH or deleting AASS to prevent lysine degradation flux) and systemic AAV9-GCDH delivery have shown efficacy in mouse
    models, restoring enzyme activity and preventing lysine diet-induced neuropathology.

    &#39;
  treatment_term:
    preferred_term: gene therapy
    term:
      id: MAXO:0001001
      label: gene therapy
  target_mechanisms:
  - target: GCDH enzymatic deficiency and disrupted lysine catabolism
    treatment_effect: RESTORES
    description: AAV-mediated GCDH replacement restores GCDH expression and enzyme activity in target tissues.
    evidence:
    - reference: PMID:38983872
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: Neonatal treatment with AAV-GCDH restores GCDH expression and enzyme activity in liver and striatum.
      explanation: Supports restoration of the primary deficient enzymatic node by gene replacement therapy.
  - target: Brain exposure to toxic GA1 catabolites
    treatment_effect: INHIBITS
    description: Liver-directed gene therapy approaches reduce pathogenic brain metabolite burden.
    evidence:
    - reference: PMID:37075130
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: the characteristic brain and lethal phenotype of the GA-1 mouse model was rescued by two different liver-directed gene therapy approaches
      explanation: Supports inhibition of the downstream toxic-catabolite brain exposure pathway.
  evidence:
  - reference: PMID:37075130
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: &#39;the characteristic brain and lethal phenotype of the GA-1 mouse model was rescued by two different liver-directed
      gene therapy approaches: Using an adeno-associated virus, we replaced the defective Gcdh gene or we prevented flux through
      the lysine degradation pathway by CRISPR deletion of the aminoadipate-semialdehyde synthase (Aass) gene.&#39;
    explanation: Preclinical evidence for two liver-directed gene therapy strategies for GA1.
  - reference: PMID:38983872
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: Neonatal treatment with AAV-GCDH restores GCDH expression and enzyme activity in liver and striatum.
    explanation: Systemic AAV9-GCDH delivery restores enzyme activity in target tissues.
  - reference: PMID:38983872
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: AAV-GCDH significantly ameliorates the striatal neuropathology, minimizing neuronal dysfunction, gliosis, and
      alterations in myelination.
    explanation: Gene therapy prevents striatal neuropathology in the GA1 mouse model.
- name: Bezafibrate (investigational)
  description: &#39;The pan-PPAR agonist bezafibrate has shown neuroprotective effects in GCDH-deficient mice by normalizing oxidative
    stress and neuroinflammation in the striatum.

    &#39;
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
    therapeutic_agent:
    - preferred_term: bezafibrate
      term:
        id: CHEBI:47612
        label: bezafibrate
  target_mechanisms:
  - target: Oxidative stress and neuroinflammation
    treatment_effect: INHIBITS
    description: Bezafibrate dampens oxidative and pro-inflammatory pathomechanisms in GCDH-deficient brain tissue.
    evidence:
    - reference: PMID:35639256
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: in vivo treatment with the pan-PPAR agonist bezafibrate normalized these alterations.
      explanation: Supports mechanistic inhibition/modulation of oxidative-inflammatory injury pathways.
  evidence:
  - reference: PMID:35639256
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: in vivo treatment with the pan-PPAR agonist bezafibrate normalized these alterations.
    explanation: Bezafibrate treatment normalized oxidative stress and inflammatory markers in GCDH-deficient mice.
  - reference: PMID:35639256
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: bezafibrate should be tested as a potential adjuvant therapy for GA1.
    explanation: Authors propose bezafibrate as a potential adjuvant therapy based on preclinical evidence.
</pre>
            </div>
        </div>

        <footer class="page-footer">
            <p>
                Generated from <a href="https://github.com/monarch-initiative/dismech" target="_blank">dismech</a>
                knowledge base
            </p>
            <p style="margin-top: 8px;">
                <a href="https://github.com/monarch-initiative/dismech/blob/main/kb/disorders/Glutaryl-CoA_Dehydrogenase_Deficiency.yaml" target="_blank">View source on GitHub</a>
            </p>
        </footer>
    </div>

    <script>
        function toggleYaml() {
            const content = document.getElementById('yamlContent');
            const toggleText = document.getElementById('yamlToggleText');
            content.classList.toggle('show');
            toggleText.textContent = content.classList.contains('show') ? 'click to hide' : 'click to show';
        }
    </script>
    <script>
        (function() {
            const banner = document.querySelector('.notice-banner');
            if (!banner) return;
            const dismiss = () => banner.remove();
            banner.addEventListener('click', dismiss);
            banner.addEventListener('keydown', (event) => {
                if (event.key === 'Enter' || event.key === ' ') {
                    event.preventDefault();
                    dismiss();
                }
            });
        })();
    </script>
</body>
</html>